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ABSTRACT 
 
The main purpose of this work is to understand how two members of the fragile X family 
of RNA binding proteins, fragile X mental retardation protein (FMRP) and FXR1P, are 
regulated by post-translational modifications and microRNAs (miRNAs), respectively.  
Both proteins play key roles in normal development and function.  The absence of FMRP 
leads to the cognitive defects seen in Fragile X syndrome, the leading cause of hereditary 
mental retardation, while loss of FXR1P expression in mice is fatal after birth, likely due 
to cardiac and muscle abnormalities.  
 
Small, genomically encoded miRNAs are involved in almost every biological process, 
specifically in the regulation of mRNA translation.  Although their biogenesis is 
relatively well defined, it is still unclear how they are recruited to their mRNA targets.  
FMRP and its autosomal paralogs, FXR1P and FXR2P, in addition to the single 
Drosophila ortholog, dFmrp, associate physically and functionally with the miRNA 
pathway. 
 
Constitutively phosphorylated FMRP (P-FMRP) is found associated with stalled 
untranslating polyribosomes and translation of at least one mRNA is downregulated 
when FMRP is phosphorylated.  We hypothesized that translational regulation by P-
FMRP is accomplished through association with the miRNA pathway.  Accordingly, we 
developed a phospho-specific antibody to P-FMRP and showed that P-FMRP associates 
with increased amounts of precursor miRNAs (pre-miRNA) compared to total FMRP.  
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Furthermore, P-FMRP does not associate with Dicer or Dicer containing complexes in 
co-immunoprecipitation experiments or in an in vitro capture assay using a P-FMRP 
peptide sequence bound to agarose beads.  These data show that Dicer containing 
complexes bind FMRP at amino acids 496-503 and that phosphorylation disrupts this 
association with a consequent increase in association with pre-miRNAs.  In sum, we 
propose that in addition to regulating translation, phosphorylation of FMRP regulates its 
association with the miRNA pathway by modulating association with Dicer.  We present 
a new model for the effect of phosphorylation on FMRP function, where phosphorylation 
of FMRP inhibits Dicer binding, leading to the accumulation of precursor miRNAs and 
possibly a paucity of activating miRNAs. 
 
FMRP’s autosomal paralog, FXR1P, plays an important role in normal muscle 
development, has been implicated in fascioscapulohumeral muscular dystrophy (FSHD) 
and its absence or misregulation has been shown to cause cardiac abnormalities in mice 
and zebrafish.  To examine miRNA-mediated regulation of FMRP and FXR1P, we 
studied their expression in a conditional Dicer knockdown cell line, DT40.  We found 
that FXR1P, but not FMRP, increases upon Dicer knockdown and consequent absence of 
miRNAs suggesting that FXR1P is regulated by miRNAs, while FMRP is not. 
Expression of a luciferase reporter bearing the FXR1 3’UTR was significantly increased 
in the absence of miRNAs, confirming miRNA-mediated regulation of FXR1P.  We 
identified one of the regulatory regions by removing an 8-nucleotide miRNA seed 
sequence common to miRNAs 25, 32, 92, 363 and 367 in the 3’UTR of FXR1.  
Accordingly, over expression of a miRNA, miR-367, containing this common seed 
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sequence decreased endogenous FXR1P expression in HEK-293T and HeLa cell lines.  
We report for the first time that FXR1P expression is regulated through miRNA binding 
to the miR-25/32/92/363/367 seed sequence binding site in the FXR1 3’UTR. 
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INTRODUCTION 
  
The main goal of my work is to understand how two members of the fragile X family of 
RNA binding proteins, fragile X mental retardation protein (FMRP) and ‘FMR1 cross 
reacting relative’ protein (FXR1P), are regulated by post-translational modifications and 
microRNAs (miRNAs), respectively. 
 
This work was conducted and all data obtained in the lab of Professor Stephanie Ceman 
and is divided into background information (chapter 1), two data chapters (chapters 2 and 
3) and finally, concluding remarks (chapter 4).  Much of the background information 
presented in chapter 1 was published in an abbreviated form as a review.  The data 
presented in chapter 2 has also been published, while chapter 3 is a manuscript that has 
been submitted for publication.   
 
Chapter 1 highlights key background information on fragile X syndrome and the fragile 
X family of proteins, progresses into regulation of target mRNAs by FMRP and, after a 
summary of miRNAs and miRNA processing, outlines what was known about the 
connection between the miRNA pathway and fragile X proteins prior to my work 
presented here.   
 
Chapter 2 describes how phosphorylation of FMRP abolishes association with Dicer, a 
protein that is a crucial component of the miRNA processing pathway, leading to an 
increase of un-processed precursor miRNAs (pre-miRNAs) associated with 
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phosphorylated FMRP (P-FMRP).  We report a new role for P-FMRP in regulating 
association with the miRNA pathway and propose a model to explain how a lack of 
mature miRNAs associated with P-FMRP could lead to translation suppression of target 
mRNAs.   
 
Chapter 3 asks the question whether miRNAs regulate expression of FMRP and FXR1P, 
in the process shifting the focus from FMRP to FXR1P, an autosomal paralog of FMRP.  
Using a conditional Dicer knockdown cell line, DT40, we show that FXR1P, but not 
FMRP, increases upon Dicer knockdown and consequent absence of miRNAs, suggesting 
that FXR1P is regulated by miRNAs while FMRP is not.  We describe how a regulatory 
region was mapped in FXR1 by luciferase assay to an 8 nucleotide miRNA seed sequence 
common to the miR-25/32/92/363/367 group of miRNAs that bind in the 3’ untranslated 
of FXR1.  We confirm this site by over expressing a miRNA, miR-367, containing this 
common seed sequence and showing that it decreased endogenous FXR1P expression in 
two human cell lines.  We report for the first time that FXR1P expression is regulated 
through miRNA binding to the miR-25/32/92/363/367 seed sequence binding site in the 
FXR1 3’UTR. 
 
The dissertation concludes in chapter 4 with a summary of this research, potential future 
experiments and a discussion of the contributions this work has made to our 
understanding of the field of fragile X syndrome and miRNA regulation of protein 
expression.  
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CHAPTER 1 
BACKGROUND 
(Originally published in part as a review in RNA Biology, Volume 6,  
Issue 2, pages 175-178, 2009) 
 
Fragile X syndrome   
Fragile X syndrome, the leading cause of hereditary mental retardation, has an occurrence 
rate of approximately 1 in 4000 males and 1 in 8000 females (Penagarikano et al., 2007).  
It is caused by the inactivation of the fragile X mental retardation gene, FMR1, due to an 
expansion of a trinucleotide repeat (CGGn) in the 5’ untranslated region of the gene 
(O'Donnell and Warren, 2002, Darnell et al., 2005, Garber et al., 2006, Penagarikano et 
al., 2007).  The FMR1 gene product, fragile X mental retardation protein (FMRP) is an 
RNA binding protein that regulates target mRNAs (Penagarikano et al., 2007, Costa-
Mattioli et al., 2009).  FMRP associates with approximately 400 mRNAs in the brain 
(Brown et al., 2001, Miyashiro et al., 2003) and is found nearly ubiquitously throughout 
the body (Terracciano et al., 2005).  High expression levels of FMRP in the brain (Weiler 
et al., 1997) and its role as a translational regulator (Laggerbauer et al., 2001, Li et al., 
2001, Costa-Mattioli et al., 2009) suggests an important role in memory, learning, and 
normal cognition as suggested by the cognitive impairment exhibited in patients with 
fragile X syndrome upon the loss of FMR1 gene expression (Terracciano et al., 2005).  
The most prominent phenotype, mental retardation, also affects spatial skills, information 
processing, and leads to language and speech deficits (Penagarikano et al., 2007).  Other 
clinical features of fragile X syndrome include facial abnormalities, machroorchidism, 
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and connective tissue disorders (Penagarikano et al., 2007).  There are also behavioral 
effects attributed to fragile X syndrome.  Patients can display hyperactivity, 
hypersensitivity to sensory stimuli, attention deficits, and 15-50% of patients exhibit 
autistic-like behaviors such as averted gaze, tactile defensiveness, and repetitive 
behaviors (Penagarikano et al., 2007).     
 
The fragile X family of RNA-binding proteins 
FMRP, the protein lacking in people with Fragile X syndrome, is one member of a small 
family of RNA binding proteins that include two autosomal paralogs, FXR1P and FXR2P 
(FXRPs) with functional domain sequence similarities to FMRP of 80% and 76% 
respectively (Penagarikano et al., 2007).  In addition to sharing similar functional 
domains, the FXRPs have the same overall cellular localization patterns as FMRP 
(Penagarikano et al., 2007) and were validated as FMRP interactors by a yeast two-
hybrid screen of a human brain cDNA library for proteins that interacted with FMRP 
(Siomi et al., 1995, Zhang et al., 1995).  FXR2P and FXR1P exhibit an overall sequence 
similarity to FMRP of 60% (Siomi et al., 1995).  However, even though cellular 
distribution is similar, tissue expression patterns differ greatly between FMRP and the 
FXRPs.  Whereas FMRP is widely expressed in most tissues, particularly brains and 
testis (Devys et al., 1993, Khandjian et al., 1995, Tamanini et al., 1999), FXR1P is highly 
expressed in muscle and heart tissues where FMRP is almost absent suggesting different 
functions for these two proteins (Bakker et al., 2000, Hoogeveen et al., 2002).  In vivo, it 
has been demonstrated that FMRP, FXR1P and FXR2P preferentially interact with  
 
 5 
themselves to form homo-multimers (Tamanini et al., 1999), however differential tissue 
distributions indicate that FMRP and the FXRPs probably do not require complex 
formation for proper function (Hoogeveen et al., 2002).   
 
Fragile X protein functional domains 
FMRP and the FXRPs share functional protein domains including a nuclear localization 
signal (NLS), a leucine-rich nuclear export signal (NES), two RNA binding domains with 
homology to hnRNP K proteins termed KH1 and KH2, and an arginine-glycine rich RNA 
binding region termed the RGG box (however, the presence of a true RGG box in FXR2P 
is controversial)  (Hoogeveen et al., 2002) (Fig. 1).  Although possessing an NLS and 
NES, FMRP and the FXRPs are localized mainly in the cytoplasm where they form 
messenger ribonucleoprotein complexes and associate with polyribosomes (Feng et al., 
1997, Ceman et al., 1999), but recent data shows that FMRP binds its target mRNAs in 
the nucleus (Kim et al., 2009).  FMRP associates with ribosomes via RNA (Khandjian et 
al., 1996), but how FMRP or the FXRPs regulate translation of  bound mRNAs at the 
molecular level is still unclear.  
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Figure 1.  Schematic of the FMR and FXR protein domains.  Shared domains are 
indicated.  NLS-nuclear localization sequence; KH1, KH2-RNA binding domains with 
homology to hnRNP K protein; NES-nuclear export sequence, RGG-RNA binding 
arginine-glycine rich region.  SNASETES-phosphorylation site in FMRP with phospho-
serines indicated.  Amino acid numbering and figure adapted from data in (Ceman et al., 
2003). 
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Alternative splicing 
The FMR1 and FXR1 transcripts are alternatively spliced.  There are several FMRP 
isoforms ranging from 69-80 kDa with the major species at 69 kDa (Ashley et al., 1993).  
At least seven FXR1P isoforms (iso-a to iso-g) have been identified (Siomi et al., 1995, 
Kirkpatrick et al., 2001) with three isoforms showing muscle specificity (Mientjes et al., 
2004).  In contrast to FMR1, the mechanism of FXR1 alternative splicing is tissue 
specific and different isoforms are expressed preferentially in certain tissues (Khandjian 
et al., 1998, Kirkpatrick et al., 1999, Tamanini et al., 2000).  Although the functional 
relevance of these tissue specific isoforms is not known, only FXR1P is expressed in 
skeletal muscle where it localizes to costameres and Z-lines (Bakker et al., 2000, Dube et 
al., 2000, Mientjes et al., 2004).   The longest FXR1P isoform is highly expressed during 
myogenesis in adult cardiac and skeletal muscle tissue and exhibits high affinity for 
mRNAs containing G-quartet structures (Bechara et al., 2007).  Some FXR1P isoforms 
and FXR2P also have a nucleolar-targeting signal (NoS) signal that is lacking in FMRP, 
again suggesting functional differences among this family of proteins (Tamanini et al., 
2000).  Although there is very little data to suggest a tissue specific function of FXR2, 
these data suggest that alternative splicing, at least in the case of FMR1 and FXR1, may 
play an important role in mRNA regulation in different tissues.  
 
FMR and FXR animal models 
Since no naturally occurring animal models for trinucleotide repeat disorders such as 
fragile X syndrome have been described, several groups have generated animal models to 
better study this disorder.  To attempt to study the underlying molecular mechanisms of 
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trinucleotide repeat amplification, mouse models for CGG repeat instability have been 
constructed to try to mimic the spontaneous expansion seen in human patients, however 
artificial insertion of triplet repeats has had little to no effect on CGG(n) stability in these 
mice (Burright et al., 1995, Goldberg et al., 1996, Lavedan et al., 1998).  Transgenic mice 
created with as many as 120 triplet repeats still did not exhibit the full expansion that 
occurs over generations in human fragile X patients (Lavedan et al., 1998).  This has led 
to the conclusion that, at least in mice, extra CGG repeats alone are not enough to induce 
the expansion and full mutation (Lavedan et al., 1998).   
 
To study the physiological and behavioral effects resulting from a lack of FMRP, a 
FMR1 knockout mouse was first engineered by utilizing homologous recombination to 
select for a neomycin cassette disruption of exon 5 in mouse genomic FMR1 DNA 
(Bakker et al., 1994).  RT-PCR and western blot analysis confirmed the absence of wild-
type FMR1 and FMRP in these mice (Bakker et al., 1994).  Absence of FMRP in this 
knockout mouse led to some of the phenotypic characteristics observed in human fragile 
X patients such as macroorchidism, hyperactivity, and problems processing spatial 
information as shown by poor performance in tests such as the Morris water maze (first 
developed by Richard Morris in 1981), where the mice must locate a hidden platform 
submerged in water (Bakker et al., 1994) .  
 
In Drosophila melanogaster the FMRP homologue, dFmrp, shares a protein domain 
sequence with human and murine FMRP of 56% overall (Zarnescu et al., 2005), 70% and 
71% for the two KH domains and 25% for the RGG box (Gao, 2002, Hoogeveen et al., 
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2002).  A number a dFmrp mutants have been generated, including dfmr1 containing the 
I307N mutation which causes a severe form of fragile X in humans (De Boulle et al., 
1993, Wan et al., 2000).  Although many behavioral tests initially indicated that dfmr1 
mutant flies did not differ significantly from wild-type flies, subsequent data show that 
mutants exhibit some locomotor function deficits as shown by impaired coordinated 
behavior in flight tests, perhaps linked to the increase of growth and branching at 
synaptic terminals seen in dfmr1 mutant flies (Zhang et al., 2001).  Mutant larvae were 
shown to exhibit altered crawling behavior with more frequent turns and shorter linear 
paths (Xu et al., 2004).  And, similar to mouse models, dfmr1 mutant flies show little to 
no rhythmicity in circadian locomotor activity, but can be rescued by an insertion of 
genomic fragment containing the wild-type dfmr1 gene (Dockendorff et al., 2002, Inoue 
et al., 2002, Morales et al., 2002).  Abnormal spermatogenesis and oogenesis in flies has 
also been linked to dfmr1 mutation (Zhang et al., 2004, Costa et al., 2005).  
 
In Drosophila, dFmrp associates with Dicer, Argonaute proteins (Ago1 and Ago2), 
microRNAs (miRNAs) and other components of the miRNA pathway (Caudy et al., 
2002, Ishizuka et al., 2002, Jin et al., 2004b, Xu et al., 2008).  Further studies 
subsequently showed that mammalian FMRP also associates with Dicer, miRNAs, Ago2 
and other miRNA pathway components (Jin et al., 2004a, Jin et al., 2004b), suggesting 
that FMRP utilizes the miRNA pathway to regulate its target mRNAs.  This will be 
discussed in greater detail in subsequent sections. 
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In contrast to FMR1 knockouts, FXR1 knockout neonates die shortly after birth, likely 
due to cardiac or respiratory failure, indicating that unlike FMRP expression, FXR1P 
expression is necessary for viability in mice (Mientjes et al., 2004). In other animals such 
as Xenopus and zebrafish, reduction of FXR1P by siRNA or morpholino knockdown 
technologies results in striated, skeletal and other muscular abnormalities (Huot et al., 
2005, Padje et al., 2009), indicating that FXR1P may play an important role in muscle 
development in multiple species.   
 
Recently, it was observed that humans with facioscapulohumeral muscular dystrophy 
(FSHD) exhibit abnormal expression patterns of three different FXR1P isoforms in 
myoblast and myotubes (Davidovic et al., 2008).  These altered expression patterns 
appear to be due to the reduced stability of specific FXR1 mRNA variants, which leads to 
a reduced expression of those isoforms in developing muscle (Davidovic et al., 2008).   
 
FXR2 knockout mice do not exhibit any clear pathology in tissues, however some 
behavioral phenotypes similar to FMR1 knockout mice have been observed (Hoogeveen 
et al., 2002).  Additional behavioral abnormalities unique to FXR2 mutants such as a 
decrease in fear conditioning, an exaggerated startle response, and a slight decrease in 
response to painful stimuli have also been reported (Bontekoe et al., 2002).  Interestingly, 
when FXR2 is knocked out in conjunction with FMR1 in mice, loss of normal rhythmic 
activity in a light-dark period is observed (Zhang et al., 2008).  These data demonstrate  
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that both FMR1 and FXR2 are required for normal circadian behavior and suggests a dual 
function of these proteins that could be relevant to the sleep alterations observed in 
human patients (Zhang et al., 2008). 
 
Post-translational modifications of fragile X proteins 
Phosphorylation is a mechanism by which protein activity can be modulated by the 
covalent addition of negatively charged phosphate groups to serine, threonine or tyrosine 
side chains.  This addition changes how the protein interacts with other proteins or 
nucleic acids and is a rapid, reversible modification that is responsible for many 
important functions within the cell (Cooper and Hausman, 2006). 
 
Phosphorylation of RNA-binding proteins, such as FMRP, can either up or down-regulate 
association with RNA (Ceman et al., 2003, Narayanan et al., 2007, Bechara et al., 2009, 
Cheever and Ceman, 2009a).  FMRP is a phospho-protein that is phosphorylated on three 
serines (496, 499, and 503) between the nuclear export sequence and the RGG box, 
which is the primary RNA binding domain (Ceman et al., 2003) (Fig. 1).  FMRP is also 
associated with stalled, untranslating polyribosomes as shown by its resistance to 
ribosomal run-off when constitutively phosphorylated (Ceman et al., 2003) which 
suggests that phosphorylated FMRP is involved in translation suppression.  In 
Drosophila, dFMRP is phosphorylated in vivo by dCKII at serine 406 with subsequent 
RNA-binding activity alteration (Siomi et al., 2002). This, among other evidence, has led 
to the proposition that phosphorylation of FMRP affects its function as a translational 
regulator of bound target mRNAs. 
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Other post-translational modifications such as glycosylation and sumolyation have not 
been reported with regard to FMRP.  However, FMRP has been shown to be affected by 
ubiquitination where a mGluR-LTD induced transient increase in FMRP is then rapidly 
degraded by the ubiquitin-proteasome pathway, suggesting a rapid cycle of synthesis and 
degradation of FMRP (Hou et al., 2006).  This cycle could be important to control mRNA 
binding and hence, synaptic plasticity (Hou et al., 2006).   
 
Arginine methylation, a post-translational modification restricted to eukaryotic cells, 
often occurs in RGG box containing proteins, including FMRP (Najbauer and Aswad, 
1990, Liu and Dreyfuss, 1995, Gary and Clarke, 1998).  Arginine methylation was 
originally shown to affect the ability of FMRP to bind homopolymers and RNAs through 
the use of an adenosine-2’, 3’-dialdehyde inhibitor (AdOx) (Denman, 2002).  
Methylation may also play a role in FMRP’s ability to bind to FXR1P in order to co-
regulate translation of target mRNAs (Dolzhanskaya et al., 2006).  Using double-label 
fluorescence confocal microscopy to visualize FMRP-containing cytoplasmic granules 
associating with translational components during oxidative stress, methylation was shown 
to regulate FMRP-homodimer and FMRP-FXR1P-heterodimer formation by influencing 
these ratios during translation initiation, suggesting an important role for methylation in 
normal FMRP function (Dolzhanskaya et al., 2006).  Subsequent work showed that 
FMRP, FXR1P, and dfmr1 are methylated on four arginines in the arginine-glycine-
glycine (RGG) box by protein arginine methyl-transferase 1 (PRMT1) in vitro  
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(Stetler et al., 2006).  Reduced binding to the sc1 RNA sequence, which contains a stem 
loop G-quartet structure, upon in vitro methylation by PRMT1 suggests that methylation 
serves to reduce or modulate target mRNA binding by FMRP (Stetler et al., 2006).    
 
Phosphorylated FMRP and regulation of mRNA translation 
FMRP is phosphorylated on three serines between its nuclear export sequence and the 
primary RNA binding domain, the RGG box, in both brain and cell lines (Ceman et al., 
2003).  To determine the role of phosphorylation on FMRP function, amino acid 
substitutions of the primary phosphorylation site were made, mimicking either 
constitutive phosphorylation or no phosphorylation (Ceman et al., 2003).  Constitutively 
phosphorylated FMRP (P-FMRP) was relatively resistant to ribosomal run-off, 
suggesting that it was associated with untranslating polyribosomes (Ceman et al., 2003).  
In contrast, unphosphorylated FMRP was easily run-off, suggesting that it was associated 
with actively translating polyribosomes (Ceman et al., 2003). Narayanan and colleagues 
identified a specific cargo mRNA, SAPAP3, whose translation was modulated by 
phosphorylation of FMRP (Brown et al., 2001, Narayanan et al., 2007).  As predicted by 
the model, inhibition of phosphatase 2A (PP2A) led to an increase in translation of 
SAPAP3 (Narayanan et al., 2007).  Consequently, it has been suggested that 
phosphorylation of FMRP functions as a key step in the regulation of bound target 
mRNAs, suppressing translation through an unknown mechanism.   
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To verify P-FMRP’s role as a suppressor of target mRNA translation, polyribosome 
profiles were performed to fractionate the 40S, 60S and 80S subunits from the heavier 
polyribosomes in cells as described in (Ceman et al., 2003).  P-FMRP localization was 
then visualized by western blot with PSER and the anti-FMRP monoclonal antibody 1C3 
(Devys et al., 1993) and P-FMRP was found on polysomes (Fig. 2 ).  To determine 
whether these polysomes are actively translating, we treated stably transfected FLAG-
tagged FMRP (WT) cells with sodium azide (NaAz).  Although pleotropic, NaAz is an 
inhibitor of translation initiation that allows visualization of ribosomal run-off of actively 
translating ribosomes while stalled ribosomes do not change their localization at the 
dense polysome fractions.  More specifically, after translation initiation is blocked, 
actively translating ribosomes continue to move along the transcript and “run-off” but no 
new translation is initiated. As published previously with a phospho-mimic transgene in 
which the serine at 499 was substituted with aspartic acid (Ceman et al., 2003), P-FMRP 
was resistant to run-off because it is associated with stalled polyribosomes in the denser 
fractions (Fig. 2-PSER).  Densitometry (NIH Image) shows approximately 75% of P-
FMRP located in dense polyribosome fractions when translation is blocked compared to 
29% of total FMRP.  The anti-FMRP (1a) antibody shows FMRP present across all 
fractions (Fig. 2-1a).  
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Figure 2.  Phospho-FMRP is associated with stalled, untranslating polyribosomes.  
Fibroblast cells containing stably transfected flag-tagged FMRP were treated with 
sodium azide and cycloheximide and harvested.  Fractions were centrifuged through a 
15-45% sucrose gradient, analyzed with UV to detect optical density, collected and TCA 
precipitated.  P-FMRP was visualized by western blot using PSER and total FMRP with 
monoclonal antibody 1a. 
 
 
 
 
 
 16 
Nuclear trafficking of FMRP 
Recent data show that upon FMRP binding to nuclear mRNAs, exit from the nucleus 
occurs via the Tap/NXF1 bulk nuclear exporter in combination with FMRP’s own 
nuclear export sequence (Kim et al., 2009) suggesting a model where once FMRP exits 
the nucleus with its bound mRNAs, translation could be modulated depending on its 
phosphorylation state (Fig. 3).  Our recent data point toward phosphorylation regulating 
association of FMRP with the miRNA pathway as a means to regulate translation of 
target mRNAs (Cheever and Ceman, 2009a) and will be described in more detail in 
chapter 2.  
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Figure 3.  Model of FMRP localization, target mRNA binding and translation 
regulation.  FMRP enters the nucleus, binds target mRNAs, and exits using a 
combination of the bulk mRNA exporter Tap/NXF1 and its own NES (Kim et al., 2009).  
Once in the cytoplasm, translation regulation of target mRNAs occurs based on FMRP’s 
phosphorylation state. 
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Non-coding RNAs  
Small, non-protein coding RNAs with important gene-regulatory function are a 
conserved feature of both prokaryotic and eukaryotic genomes. They can perform diverse 
biological functions in a multitude of cellular processes, including gene silencing at the 
transcriptional or post-transcriptional level (Bartel, 2004a, Meister, 2007). Classes of 
non-coding RNAs can be distinguished based on their mechanisms of biogenesis, 
precursor structure and the genomic region from which they originate (Farazi et al., 
2008).  Piwi interacting small RNAs (piRNAs), implicated in mRNA cleavage, and 
repeat-associated siRNAs (rasiRNAs), involved in regulation of chromatin structure, are 
derived from transcripts that are not double stranded (ds) (Farazi et al., 2008).  However, 
the most well-studied classes of small RNAs are siRNAs and miRNAs that can be 
grouped together based on their origination from dsRNA precursors.  siRNAs, processed 
from dsRNAs, were the first small RNA discovered to regulate gene expression by 
binding in a sequence-specific manner in order to initiate target degradation (Fire et al., 
1998, Zamore et al., 2000).  miRNAs, first characterized in C. elegans (Lee et al., 1993), 
are the most abundant class of small RNAs in animals, are 19-25 nucleotides in size and 
are genomically encoded (Ambros, 2004, Bartel, 2004a, Farazi et al., 2008).  They can be 
expressed at extremely high levels, up to ten thousands of copies per cell, potentially 
regulating many hundreds of mRNA targets (Lim et al., 2003).         
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Processing of microRNAs 
miRNAs function by base pairing with sequences in the 3’UTR of their target mRNA 
sequences.  If base-pairing is perfect along their ~22 nucleotide length, the result is 
mRNA target degradation.  In contrast, if base-pairing is imperfect with a bulge in the 
duplex, the result is translational silencing (Bartel, 2004b).  The most recent miRBase 
update (Release 14.0, Sept. 2009, http://www.mirbase.org/), lists 10,581 mature miRNAs 
from 115 species.  Since each miRNA could potentially interact with multiple mRNAs 
due to incomplete base pairing to each target, it has been bioinformatically predicted that 
more than 30% of human genes could be regulated by miRNAs (Ross et al., 2007). 
 
The role of Dicer in miRNA processing 
In mammals, primary miRNAs are transcribed in the nucleus and processed into 70-80 nt 
precursor miRNAs by Drosha and DGCR8 (Lee et al., 2003).  Precursor miRNAs (pre-
miRNAs) are exported to the cytoplasm by exportin 5 (Yi et al., 2003), where they are 
processed into short, double stranded duplexes by the Dicer pre-miRNA processing 
complex (Lee et al., 2003, Bartel, 2004a, Ross et al., 2007). Dicer is a key protein in this 
complex, because it processes the pre-miRNAs into shorter (21-23 nt) double-stranded 
segments which can then be inserted into the RNA induced silencing complex (RISC) 
(Perron and Provost, 2008). The RNA induced silencing complex then separates the 
duplexed strands into a mature miRNA (Bartel, 2004a) (Fig. 4).  This guide miRNA 
associates with Ago2, which is the only human Argonaute family protein with 
endonuclease activity (Song et al., 2003, Fillipowicz et al., 2005, Hock and Meister, 
2008).  Incomplete complementarity of the miRNA to its target mRNA leads to 
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translational repression (or in some cases activation, as discussed later) while complete 
complementarity triggers Ago2’s endonuclease activity leading to cleavage of the target 
mRNA, as observed during RNA silencing.  Conversely, in Drosophila, both Ago1 and 
Ago2 have cleavage activity, with Ago1 mediating miRNA guided cleavage of RNA and 
Ago2 mediating siRNA cleavage during RNA silencing (Hock and Meister, 2008).  
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Figure 4.  microRNA processing diagram.  Primary miRNAs are transcribed in the 
nucleus and processed into precursor miRNAs by the Drosha/DGCR8 complex.  After 
being exported to the cytoplasm by Exportin 5, the Dicer complex cleaves the precursor 
miRNA into a double stranded duplex miRNA.  One strand is degraded and the other is 
processed further and inserted into RISC to produce a mature miRNA.  This miRNA is 
now ready to bind a target mRNAs in order to effect degradation, translation suppression, 
or deadenylation depending on the miRNA’s complementarity to the target. 
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Although it is unknown exactly how the mature miRNA finds its target mRNA, miRNAs 
function as part of larger complexes such as the RNA induced silencing complex (RISC) 
and the miRNA ribonucleoprotein (miRNP) complex, suggesting that miRNAs guide 
associated proteins to target mRNAs to effect degradation, repression, or in some cases, 
translation activation (Fillipowicz et al., 2005, Vasudevan and Steitz, 2007, Vasudevan et 
al., 2007).  Although both structure and homology studies of Argonaute explain its 
“slicing” role, there is no similar evidence explaining its role in translation repression 
(Fillipowicz et al., 2005).  Ago proteins in conjunction with miRNAs bound with 
incomplete complementarity to mRNA targets can mediate repression by RNA 
degradation or inhibition of translation (Hock and Meister, 2008).  Degradation occurs 
when an Ago-miRNA complex binds a target and induces deadenylation, decapping, and 
degradation (Chen and Meister, 2005, Hock and Meister, 2008).  Alternatively, an Ago-
miRNA complex can bind target mRNAs and suppress translation by blocking ribosome 
read-through (Chen and Meister, 2005, Hock and Meister, 2008).  The mechanism by 
which Ago proteins mediate translational repression is still under debate; it is not yet 
clear whether they act on translation initiation (Meister, 2007), or on translation 
elongation (Olsen and Ambros, 1999, Maroney et al., 2006, Petersen et al., 2006).  
Neither of these suppressive roles for argonaute can be explained strictly by its structural 
role as a cleaver of RNA, leading to the assumption that there are other associated 
proteins within the miRNP complex that enable translational control (Hock and Meister, 
2008).  
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Processing bodies  
Once mRNAs have been targeted by miRNAs for degradation (because of complete 
complementarity) or suppression (incomplete complementarity), they move into 
cytoplasmic foci.  These foci were first observed in yeast and subsequently named 
processing bodies (PBs) (Kedersha and Anderson, 2007), where mRNPs colocalize with 
machinery for translation repression and mRNA decay (Parker and Sheth, 2007).  
Although the environment of PBs is highly dynamic, decapping machinery including 
Dcp1p/Dcp2p and activators of Dcp proteins have been found there along with, under 
certain stress conditions, nonsense-meditated decay pathway proteins (Parker and Sheth, 
2007).  PBs require mRNA to form, as shown by their disruption upon RNase treatment 
and the observation that overexpression of a nontranslating mRNA increases their size in 
yeast (Teixeira et al., 2005).   
 
PBs are also called GW bodies because they contain the protein GW182, an RNA 
binding protein first observed in discrete foci in HeLa cells (Eystathioy et al., 2002).  
Knockdown of GW182 with siRNAs results in a loss of GW bodies/PBs, leading to the 
conclusion that GW182 is a necessary component of PBs, as well as a useful marker for 
immunofluorescent visualization in cells (Yang et al., 2004, Liu et al., 2005).   
 
The role of microRNAs in muscle development 
In addition to FXR1P being implicated in normal muscle development (Mientjes et al., 
2004, Huot et al., 2005), miRNAs are also critically important for normal muscle 
development and function (Wienholds and Plasterk, 2005, Chen et al., 2006, Chen et al., 
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2009).  Several miRNAs, miR-1, miR-133a and miR-206, are expressed specifically in 
muscle tissue where they promote myogenesis by targeting transcriptional repressors of 
muscle gene expression or enhance myoblast proliferation in order to inhibit myogenesis 
(Baskerville and Bartel, 2005, Chen and Lodish, 2005, Chen et al., 2006, Kim et al., 
2006, Rao et al., 2006, Sweetman et al., 2008).  Recently, it was shown that alterations in 
expression of miR-221 and miR-222 in myoblasts and myotubes disrupts the formation of 
sarcomeres in myotubes (Cardinali et al., 2009).  Comprehensive miRNA expression-
profiling studies revealed that 185 miRNAs were dysregulated in samples of diseased 
muscle tissue from ten different muscle disorders (Eisenberg et al., 2009).  Specifically, 
miR-92, one of the candidate miRNAs we found to regulate FXR1P, was shown to be 
misregulated in Duchennes’ Muscular Dystrophy and in Nemaline Myopathy, a 
congenital myopathy (Eisenberg et al., 2009).  Data showing that FXR1P is regulated by 
miRNAs will be further discussed in chapter 3. 
 
FMRP and processing bodies 
Whether FMRP localizes to PBs is controversial.  One study reported that FMRP 
localizes to approximately 50% of granules containing the GW182 marker as shown by 
immunofluoresence in astrocytoma cells, suggesting that it is present in PBs (Moser et 
al., 2007).  Further, dFmrp colocalizes with Dcp1p and other known PB proteins (Barbee 
et al., 2006).  However, in a study using HeLa cells, the majority of FMRP was found not 
to colocalize with Dcp1p, but was instead found in stress granules (Didiot et al., 2008).  
Thus, whether FMRP is localized to PBs may depend on the cell system under study. 
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FMRP association with the microRNA pathway 
Since FMRP has been found associated with miRNAs and Ago2 (Jin et al., 2004a, Jin et 
al., 2004b) and is a known translational regulator which can both activate (Brown et al., 
2001, Bechara et al., 2009) and suppress translation (Laggerbauer et al., 2001, Li et al., 
2001, Costa-Mattioli et al., 2009), it likely plays an important role in miRNA mediated 
translation regulation.  However, although FMRP associates with components of the 
miRNA pathway, it is also controversial whether it plays an important or essential role in 
the function of the miRNA pathway itself.  As described above, Didiot and colleagues 
reported that FMRP localizes separately from RISC machinery components and PBs 
(Didiot et al., 2008).  Further, they showed that FMRP was not required for RISC 
function in transfection studies with reporter constructs bearing miRNA target sequences 
(Didiot et al., 2008).  In contrast, Plante and colleagues showed that FMRP was required 
for efficient RNA silencing using reporter constructs expressed in murine fibroblast cells 
(Plante et al., 2006).  They also demonstrated that FMRP directly associates with 
miRNAs, possibly through the hnRNP K homology domains, to aid assembly of Dicer 
processed miRNAs onto target mRNAs in vitro (Plante et al., 2006).  Taking this a step 
further, Xu and colleagues showed that dFmrp was required for assembly of the Dicer-
Ago complex, and in the absence of dFmrp, there were fewer complexes, which may 
explain the reduced levels of the miRNA 124a (miR-124a) (Xu et al., 2008).  They 
concluded that dFmrp was required for normal neuronal miRNA levels during 
development, likely because it was necessary for assembly of Dicer with Ago (Xu et al., 
2008).  Differing conclusions about whether FMRP is required for normal function of the 
miRNA pathway may be due to the use of different cell systems or the evaluation of 
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different miRNAs which are developmentally timed and tissue specific (Bartel, 2004a).  
Regardless of FMRP’s role in RISC function, it is still possible that FMRP utilizes the 
miRNA pathway for translation regulation of its cargo mRNAs. 
 
The fragile X family proteins and translation activation  
Co-expression of the FXR proteins at synapses in patients with Fragile X syndrome 
demonstrates that the FXRPs cannot completely compensate for lack of FMRP (Weiler 
and Greenough, 1999, Hoogeveen et al., 2002), suggesting different  functions for the 
paralogs.  At the molecular level, recent data show that miRNAs bound to the 3’ 
untranslated region (3’UTR) of the TNFα gene in quiescent cells recruit both Ago2 and 
FXR1 proteins, resulting in upregulation of translation (Vasudevan and Steitz, 2007, 
Vasudevan et al., 2007).  The transition between translation upregulation and repression 
by the AGO2/FXR1 containing miRNPs occurs based on cell cycle (Vasudevan et al., 
2007).   
 
Translation activation by fragile X family member FMRP has also been proposed when a 
subset of mRNA cargoes were found decreased on polysomes in the absence of FMRP 
(Brown et al., 2001), suggesting that FMRP was required for their translation. Further, a 
recent study found increased translation of known mRNA cargo (Sod1) through binding 
by the C terminus of FMRP, revealing the start codon, and leading to translation initiation 
(Bechara et al., 2009).  Thus, fragile X family members FXR1P and FMRP have both 
been shown to activate translation of some mRNAs. 
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The role of fragile X proteins in the miRNA pathway 
As described above, FMRP associates with many components of the miRNA pathway 
and localizes to PBs in some systems (Caudy et al., 2002, Ishizuka et al., 2002, Jin et al., 
2004b, Barbee et al., 2006, Moser et al., 2007).  Morphological data show that loss of 
FMRP in mouse or Drosophila causes defects in spine and synapse formation (Gao, 
2007).  Taken together, a role for FMRP in neuronal development mediated through the 
miRNA pathway seems likely.  Phosphorylation of FMRP provides a rapid and reversible 
way to modulate FMRP’s association with the miRNA pathway. Since FMRP 
phosphorylation and miRNAs are both mechanisms for translation regulation of target 
mRNAs, one question addressed in my research and presented in chapter 2 is whether 
phosphorylation regulates association of FMRP with the miRNA pathway.   
 
In addition, although there is much interest in determining the mechanism by which the 
fragile X family of RNA binding proteins regulate expression of target mRNAs, the 
regulation of these translation regulators is not well understood.  Chapter 3 details the 
evidence on how the expression of FXR1P, but not FMRP, is regulated by miRNA 
binding in the FXR1 3’UTR. 
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CHAPTER 2 
PHOSPHORYLATION OF FMRP INHIBITS ASSOCIATION WITH DICER 
(Data presented in this chapter were originally published in RNA, Volume 15,  
Number 3, pages 362-366, 2009) 
 
Summary 
Fragile X syndrome is caused by an absence of the protein product of the fragile X 
mental retardation gene (FMR1).  The fragile X mental retardation protein (FMRP) is an 
RNA binding protein that regulates translation of associated mRNAs, however, the 
mechanism for this regulation remains unknown.  Constitutively phosphorylated FMRP 
(P-FMRP) is found associated with stalled untranslating polyribosomes and translation of 
at least one mRNA is downregulated when FMRP is phosphorylated.  Based on our 
hypothesis that translational regulation by P-FMRP is accomplished through association 
with the microRNA (miRNA) pathway, we developed a phospho-specific antibody to P-
FMRP and showed that P-FMRP associates with increased amounts of precursor 
miRNAs (pre-miRNA) compared to total FMRP.  Furthermore, P-FMRP does not 
associate with Dicer or Dicer containing complexes in co-immunoprecipitation 
experiments or in an in vitro capture assay using a P-FMRP peptide sequence bound to 
agarose beads.  These data show that Dicer containing complexes bind FMRP at amino 
acids 496-503 and that phosphorylation disrupts this association with a consequent 
increase in association with pre-miRNAs.  In sum, we propose that in addition to 
regulating translation, phosphorylation of FMRP regulates its association with the 
miRNA pathway by modulating association with Dicer.  
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Introduction 
Fragile X Syndrome is the most common form of inherited mental retardation and is 
caused by the absence of expression of the fragile X mental retardation protein, FMRP.  
FMRP is an RNA binding protein that binds a subset of mRNAs (Terracciano et al., 
2005).  FMRP is phosphorylated on three serines between its nuclear export sequence and 
its primary RNA binding domain, the RGG box, and is associated with stalled, 
untranslating polyribosomes when constitutively phosphorylated (Ceman et al., 2003).  
These data suggest that phosphorylated FMRP (P-FMRP) is involved in mRNA 
translational suppression, although the mechanism by which this occurs remains unclear.  
MicroRNAs (miRNAs) are short RNA sequences (21-23 nucleotides) that bind and 
regulate mRNAs through imperfect base-pairing interactions with the 3’ untranslated 
region (3’UTR) of target transcripts (Lee et al., 1993, Bartel, 2004b, Perron and Provost, 
2008).  Although originally described as suppressing translation of all target mRNAs 
(Ambros & Lee, 2001; Nottrott et al., 2006), miRNAs have recently been shown to be 
present on actively translating polyribosomes and to activate translation of some target 
mRNAs (Maroney et al., 2006; Vasudevan & Steitz, 2007; Vasudevan et al., 2007).  
miRNAs are transcribed in the nucleus by RNA polymerase II and then processed into 80 
nucleotide precursor segments by the Drosha/DGCR8 protein complex (Lee et al., 2003; 
Denli et al., 2004; Gregory et al., 2004; Han et al., 2004).  These precursor miRNAs (pre-
miRNA) are exported to the cytoplasm by exportin 5 (Yi et al., 2003), where they 
associate with the pre-miRNA processing complex (Bartel 2004, Jin 2004a) and are  
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processed by Dicer into shorter (21-23 nucleotide) double-stranded segments that can 
then be inserted into the RNA induced silencing complex (RISC) (Hammond et al., 2001; 
Bartel, 2004).    
 
Dicer and other components of the miRNA pathway associate with the Drosophila 
ortholog of FMRP (Caudy et al., 2002; Ishizuka et al., 2002).  Subsequent studies showed 
that mammalian FMRP also associated with miRNAs, as well as Argonaute 2 (AGO2) 
(Jin et al., 2004b), the protein necessary for RNAi pathway cleavage and silencing of 
mRNAs (Hutvagner & Simard, 2008).  Recently, the autosomal paralog of FMRP, FXR1, 
was found to be required for translational activation of the miRNA complex regulating 
TNFα expression (Vasudevan and Steitz, 2007).  
 
In addition to its RGG box, FMRP has two hnRNP K homology (KH) domains 
(Terracciano et al., 2005).  In vitro, recombinant FMRP aids assembly of Dicer-processed 
miRNAs onto target mRNAs by acting as an acceptor protein through its KH2 domain 
(Plante et al., 2006).  Further, FMRP is required for efficient RNAi in cells using 
luciferase reporters in gene silencing assays (Plante et al., 2006).  Taken together, these 
data point toward a mechanism whereby FMRP regulates translation of mRNAs through 
a miRNA-mediated mechanism.   The goal of this study was to investigate the 
relationship between FMRP and the miRNA pathway as a mechanism by which FMRP 
can regulate translation of its bound mRNAs.  
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Results and Discussion 
We began this study by creating a phospho-specific antibody to FMRP (PSER) using the 
eight amino acid sequence that includes three serines identified as the sole 
phosphorylation sites in FMRP: serine (ser) 499 as the primary phosphorylation site and 
ser496 and ser503 as secondary sites (Fig. 5A) (Ceman et al., 2003).  To determine 
whether the PSER antibody was specific to P-FMRP, western blots were performed on 
extracts from cells stably expressing FMRP (WT), an empty vector (VC), or an alanine 
substitution at serine 499 (S499A) variant of FMRP that cannot be phosphorylated (Fig. 
5B) (Ceman et al., 2003; Narayanan et al., 2007).  The PSER antibody did not detect 
unphosphorylated FMRP in the S499A FMRP cells but did detect P-FMRP in WT cells 
(Fig. 5B). A longer exposure revealed endogenous P-FMRP in the L-M(TK-) cells (data 
not shown), which express low levels of FMRP (Ceman et al., 1999).  As further 
evidence that PSER is phospho-specific, phosphatase treatment of immunoprecipitated 
Flag-FMRP completely eliminated reactivity with the PSER antibody (Fig. 5C).  
Together, these results indicate that the PSER antibody is specific for P-FMRP.  Further 
evidence for the specificity of this reagent was also described using neuronal preparations 
(Narayanan et al., 2007).  At the same time, we developed an antibody (NP) that detects 
the same 8 amino acid region as PSER (SNASETES) but that recognizes FMRP 
regardless of its phosphorylation state.  Although FXR1 and FXR2 contain regions 
somewhat similar to FMRP, (SNPSETES) and (STASETES), respectively, the NP 
antibody is specific for FMRP and does not detect FMRP’s autosomal paralogs (Fig. 5D).  
 32 
 
Figure 5.  PSER is specific for phosphorylated FMRP.  (a) Schematic representation 
of the FMR1 protein.  NSL-nuclear localization sequence, NES-nuclear export sequence, 
phospho-serines 496, 499, and 503 [adapted from (Ceman et al., 2003)].  (b)  Western 
blot of whole cell lysates from VC, WT and S499A FMRP expressing cells was 
immunoblotted (ib) with the indicated antibody:  PSER, 1a (anti-FMRP 1a-1C3 (Devys et 
al., 1993)) or eIF5.  (c)  Anti-Flag immunoprecipitations (IP) of Flag-FMRP expressing 
L-M[TK-] cells were split and mock treated or phosphatase (P-tase) treated (Ceman et al., 
2003) before probing with PSER of 1a (anti-FMRP).  Ig-immunoprecipitating antibody 
alone.  (d)  Flag-FMRP expressing L-M[TK-] cells immunoprecipitated with NP  
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Figure 5.  (cont.) 
antibody and probed with 1a (anti-FMRP), FXR1 (Hoogeveen et al., 2002), or FXR2 
(Siomi et al., 1995) antibodies.  WCL-L-M[TK-] whole cell lysate.  Ig-NP antibody 
alone. 
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Because P-FMRP has been shown to suppress translation of target mRNAs (Ceman et al.,  
2003; Narayanan et al., 2007), we hypothesized that the miRNA pathway might play a 
mechanistic role in the translational regulation of target mRNAs by P-FMRP.  To 
determine if the phosphorylation state of FMRP changes its association with miRNAs, 
we used the NP antibody, which detects amino acids 496-503, irrespective of the 
phosphorylation state, and the PSER antibody (Fig. 5) to immunoprecipitate total FMRP 
and P-FMRP, respectively.  Associated RNAs were then extracted and end-labeled with 
32P cytidine bisphosphate (Fig. 6A).  As shown in Figure 6B, both antibodies capture 
similar amounts of FMRP.  Surprisingly, comparisons between these samples indicated a 
large amount of 80 nt RNAs associated with P-FMRP (Fig. 6A, top).  The size of these 
RNAs corresponds to the size of precursor miRNAs that have been exported from the 
nucleus but have not yet been processed by Dicer into mature miRNAs (Jin et al., 2004b).  
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Figure 6.  P-FMRP associates with increased amounts of precursor miRNAs.  (a)  2 
x 109 Flag-FMRP cells were immunoprecipitated with pre-immune serum (pre), NP or 
PSER.  RNA was extracted and end-labeled with P32 as described (Duan and Jin, 2006), 
resolved on a 15% acrylamide TBE/urea gel and visualized using autoradiography (8 
hrs.).  The longer exposure of the gel (16 hrs.-right) shows putative associated miRNAs.  
Decade marker system (Ambion) indicates RNA size in nucleotides.  (b)  Equivalent 
amounts of FMRP were immunoprecipitated by PSER and NP antibodies in (a). 
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Since P-FMRP associates with large amounts of a precursor miRNA size RNA species, 
we hypothesized that Dicer does not associate with P-FMRP and was therefore not 
present to process precursor miRNAs into mature miRNAs.  To test this, we 
immunoprecipitated total FMRP and P-FMRP from HeLa cells, probed with a Dicer 
antibody that is specific for human Dicer and visualized the co-immunoprecipitated 
proteins by western analysis.  As shown in Fig. 7A, Dicer is associated only with total 
FMRP and not with P-FMRP.  To investigate whether the Dicer-FMRP association was 
mediated by RNA, FMRP was immunoprecipitated from WT cells and then treated with 
RNase (+) or not (-), and examined for association with Dicer (Fig. 7B).  RNase 
treatment had no effect on the FMRP-Dicer association, suggesting a protein interaction 
between Dicer and FMRP.  
 
To test whether Dicer, or a Dicer-containing complex, directly interacts with FMRP at its 
phosphorylation site, we compared the ability of Dicer to be captured by beads linked to 
the eight amino acid phospho-peptide sequence of FMRP (SNA[pS]ETES) or the 
corresponding unphosphorylated FMRP peptide sequence (SNASETES).  In Fig. 7C, 
Dicer is only captured by the non-phosphorylated SNASETES peptide and not by the 
phosphorylated peptide sequence or a random peptide sequence (Abelson et al., 2005).  
Thus, Dicer association with FMRP requires unphosphorylated region 496-503.  This 
result also rules out the possibility that PSER binding to FMRP blocks Dicer association. 
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Figure 7.  P-FMRP is unable to associate with Dicer.  (a)  Lysate from 2 x 107 HeLa 
cells was immunoprecipitated with NP or PSER antibodies and immunoblotted (ib) with 
Dicer antibody FMRP (1a) antibody.  (WCL)- 50 µg HeLa whole cell lysate.  IP-
immunoprecipitations; Ig-immunoprecipitating antibody alone.  (b)  Lysate from 109 
Flag-FMRP –expressing cells was immunoprecipitated with anti-FMRP antibody 7G1 
(Brown et al., 2001), split and incubated with either RNase (+) of mock-treated (-) and 
immunoblotted (ib) with the Dicer antibody.  (WCL)- 50 µg whole cell lysate.  (c)  
Lysate from 107 HeLa cells was incubated with matrix-coupled peptide  
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Figure 7.  (cont.) 
(NH2-SNA[pS]ETES-CONH2) (P-FMRP), (NH2-SNASETES-CONH2) (FMRP), or a 
random peptide (RP) (KETAAAKFERQHMDS), resolved on a 6% SDS-PAGE gel and 
immunoblotted with Dicer antibody. 
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In summary, we originally set out to test the hypothesis that phosphorylation of FMRP 
inhibits translation of its mRNA cargoes by preferentially associating with miRNAs.  In 
fact, we found that P-FMRP associates with an increased amount of precursor miRNAs, 
likely due to its inability to bind Dicer.  We then demonstrated that Dicer binds 
unphosphorylated FMRP on residues 496-503.  Thus, we propose a new role for 
phosphorylation in the regulation of FMRP function where phosphorylation inhibits 
FMRP association with Dicer, a key enzyme in the generation of miRNAs.  As a 
consequence of reduced association with Dicer, we predict a paucity of miRNAs 
available for association with the mRNAs bound by P-FMRP.  If miRNAs are required 
for translation activation as recently described (Maroney et al., 2006; Vasudevan & 
Steitz, 2007; Vasudevan et al., 2007), then phosphorylation would suppress translation 
indirectly by decreasing miRNA production through loss of Dicer binding. Further study 
is required to investigate whether there is translation activation of mRNAs by miRNAs 
associated with non-phosphorylated FMRP.  
 
We conclude that Dicer-FMRP association requires FMRP’s unphosphorylated region 
496-503 and that phosphorylation of FMRP abolishes this interaction.  This is a new role 
for phosphorylation in regulating FMRP function by modulating association with Dicer 
and the miRNA pathway.  If miRNAs are required for translation activation (Vasudevan 
and Steitz, 2007, Vasudevan et al., 2007) and FMRP is involved in translation activation 
(Bechara et al., 2009), phosphorylation of FMRP would indirectly suppress translation by 
decreasing miRNA production through loss of Dicer binding (Fig. 8). 
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Figure 8.  Potential regulatory role of P-FMRP in translation regulation  
Unphosphorylated FMRP associates with Dicer (top left).  The Dicer containing complex 
then processes pre-miRNAs into mature, double-stranded duplex miRNAs (bottom left).  
After RISC separates the duplex strands, the single-stranded mature miRNA binds 
FMRP’s target mRNA to induce translation.  Conversely, when FMRP is phosphorylated, 
Dicer cannot bind and pre-miRNAs are not processed into mature miRNAs (top right).  
Without activating miRNAs, translation of the target mRNA cannot occur and the result 
is indirect suppression of translation by FMRP due to loss of Dicer binding.   
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Material and Methods 
Cell lines and antibodies.  Stably transfected L-M(TK-) cells were created and 
maintained as described (Ceman et al., 2003).   Non-adherent HeLa cells were maintained 
in Joklik + HEPES + 5% NBCS (HyClone).  The rabbit anti-phospho-FMRP specific 
antibody (phospho-serine or PSER) was raised against the phospho-FMRP peptide NH2-
CNSEA(pS)Na(pS)ETE(pS)DHRDE) (Abgent).  The rabbit anti-FMRP antibody (NP) 
was obtained at the same time.  Anti-FMRP antibody IAC-1C3, hereafter referred to as 
monoclonal antibody 1a (Devys et al., 1993) was generously provided by Dr. Jean-Louis 
Mandel and was used in immunoblots where indicated.  The anti-Flag coupled agarose 
matrix (Sigma) was used to immunoprecipitate Flag-tagged FMRP in the phsopho-
specific antibody characterization experiments.  Anti-eukaryotic initiation factor 5 (eIF5) 
(Santa Cruz) was used as a loading control.  Mouse anti-Dicer (Abcam) was used to 
detect the Dicer enzyme in co-immunoprecipitation.  Rabbit anti-Dicer (Santa Cruz) was 
used to detect Dicer in the capture assay.  Antibody reactivity was visualized using either 
an anti-mouse HRP conjugate (Jackson Immunoresearch) or an anti-rabbit HRP 
conjugate (GE Healthcare) and developed with ECL (GE Healthcare). 
 
P-FMRP and NP antibody characterizations.  Whole cell extracts of L-M(TK-) cells 
stably expressing WT, S499A, or vector control (VC) were resolved by 7.5% SDS-
PAGE, transferred to Hybond-P PVDF (GE Healthcare) and probed with 1/454 dilution 
of PSER, 1/10 of 1a hybridoma supernatant or 1/10,000 of anti-eIF5.  107 Flag-FMRP 
expressing L-M(TK-) cells were lysed in 1ml of lysis buffer (50mM Tris pH 7.6, 300 
mM NaCl, 30mM EDTA, 0.5% triton X-100) and immunoprecipitated with the anti-Flag 
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antibody for 2 hours.  After two washes, the immunoprecipitate (IP) was split and either 
mock-treated or treated with 7.5 ul of shrimp alkaline phosphatase (US Biochemical) for 
30 minutes at 37°C (Ceman, et al. 2003).  The IPs were resolved by SDS-PAGE and 
probed with the phospho-FMRP antibody (PSER), as described above.   L-M[TK-] cells 
were lysed and immunoprecipitated as described above except NP antibody was used, 
resolved by SDS-PAGE, and then probed with either anti-FMRP (1a), FXR1, or FXR2 as 
described above. 
   
Precursor miRNA isolation and detection.  2 x 109 Flag-FMRP expressing L-M(TK-) 
cells were lysed in 40 mls of lysis buffer (10mM HEPES, 150mM NaCl, 30mM EDTA, 
0.5% triton X-100) and 500ul was removed for a parallel immunoprecipitation.  Lysates 
were immunoprecipitated with 40 ug NP (total FMRP), 2 ug PSER (phospho-FMRP) 
antibodies coupled to protein A sepharose (PAS) (Roche) or 100 ul pre-immune serum 
coupled to PAS.  Total RNA was extracted by phenol chloroform/ethanol precipitation of 
the immunoprecipitations.  The RNA was end-labeled with P32 cytidine bis-phosphate 
(Perkin Elmer), and resolved on a 15% TBE/urea gel as described (Duan & Jin, 2006).  
The decade size marker system (Ambion) was labeled with P32-CTP and used to size the 
resulting RNA.  Parallel immunoprecipitations were probed for FMRP (1a).   
 
Dicer immunoprecipitation.  2 x 107 HeLa cells were lysed in lysis buffer (10mM 
HEPES, 150mM NaCl, 30mM EDTA, 0.5% triton X-100) and 50ug of protein was 
removed for a whole cell lysate.  The extract was then split and immunoprecipitated with  
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either an NP antibody (total FMRP) or PSER (phospho-FMRP) for 2 hours, washed and 
resolved on a 6% SDS-PAGE gel.  After transfer, blots were probed with antibodies for 
Dicer and FMRP as described above. 
 
RNase treatment.  109 WT Flag-FMRP expressing cells were lysed (see above) and 
50ug protein removed for a whole cell lysate control.  The extract was 
immunoprecipitated with 7G1 FMRP antibody for 2 hours.  After washing, the extract 
was split and half treated with RNase (Sigma) for 20 minutes at 37°C and resolved on a 
6% SDS-PAGE gel.  Blot was probed with Dicer antibody as described. 
 
Capture assay.  4 x 107 HeLa cells were lysed (10mM HEPES, 150mM NaCl, 30mM 
EDTA, 0.5% triton X-100) and the post-nuclear, cytoplasmic supernatant was incubated 
at 4o C for 2 hours with 10 ug matrix-coupled non-phosphorylated FMRP peptide 
sequence (NH2-SNASETES-CONH2) (BioSource), phosphorylated FMRP peptide 
sequence (NH2-SNA[pS]ETES-CONH2) (BioSource), or a random peptide sequence.  
After capture, the beads were washed 3 times for 10 minutes with one additional 10 
minute wash in 0.3M lysis buffer.  The protein was resolved on a 6% SDS-PAGE gel and 
transferred to PVDF for probing with the Dicer antibody.   
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CHAPTER 3 
FRAGILE X PROTEIN FAMILY MEMBER FXR1P IS REGULATED BY 
MICRORNAS 
(Manuscript submitted for publication, RNA, November, 2009) 
 
Summary 
FXR1P is one of two autosomal paralogs of the fragile X mental retardation protein 
FMRP.  Absence of FMRP causes fragile X syndrome, the leading cause of hereditary 
mental retardation.  FXR1P plays an important role in normal muscle development and 
has been implicated in fascioscapulohumeral muscular dystrophy (FSHD).  Its absence 
also causes cardiac abnormalities in both mice and zebrafish.  To examine miRNA-
mediated regulation of FMRP and FXR1P, we studied their expression in a conditional 
Dicer knockdown cell line, DT40.  We found that FXR1P, but not FMRP, increased upon 
Dicer knockdown and the consequent reduction of miRNAs, suggesting that FXR1P is 
regulated by miRNAs while FMRP is not.  Expression of a luciferase reporter bearing the 
FXR1 3’UTR was significantly increased in the absence of miRNAs, confirming miRNA-
mediated regulation of FXR1P.  We identified one of the regulatory regions by removing 
an 8-nucleotide miRNA seed sequence common to miRNAs 25, 32, 92, 363 and 367 in 
the 3’UTR of FXR1. Accordingly, over expression of a miRNA mimic containing this 
common seed sequence decreased endogenous FXR1P expression in HEK293 and HeLa 
cell lines.  We report for the first time that FXR1P is regulated through miRNA binding 
to the miR-25/32/92/363/367 seed sequence binding site. 
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Introduction 
FXR1P is one member of a small family of three RNA binding proteins that include the 
fragile X mental retardation protein (FMRP) and FXR2P (Siomi et al., 1995, Zhang et al., 
1995).  Although FXR1P is found throughout the body, it is highly expressed in muscle 
and heart tissue where FMRP and FXR2P are mostly absent (Devys et al., 1993, Coy et 
al., 1995, Khandjian et al., 1995).  FXR1P has seven isoforms (Kirkpatrick et al., 2001, 
Mientjes et al., 2004) including one cardiac-specific isoform (Khandjian et al., 1998) and 
three muscle-specific isoforms (Mientjes et al., 2004).  FXR1P expression is essential for 
postnatal viability; inactivation of FXR1P in mice leads to impaired myogenesis resulting 
in death of neonates shortly after birth, most likely due to cardiac or respiratory failure 
(Mientjes et al., 2004).  Histochemical analyses of both skeletal and cardiac muscles 
showed a disruption of cellular architecture and overall structure in the FXR1 knockout 
mice compared to WT littermates (Mientjes et al., 2004).  In addition, reduction of 
FXR1P was shown to disrupt MyoD expression and somite formation in Xenopus, while 
re-introduction of long and short FXR1 mRNA variants rescued these muscle-specific 
effects (Huot et al., 2005).  In zebrafish, abnormalities in striated muscle and severe 
cardiomyopathy resulting in heart failure were observed in embryos after knockdown of 
FXR1 with a morpholino (Padje et al., 2009).  Lastly, altered expression of muscle 
specific isoforms of FXR1P have been implicated in facioscapulohumeral muscular 
dystrophy (FSHD) because patients have abnormal expression patterns of three different 
FXR1P isoforms in myoblasts and myotubes (Davidovic et al., 2008).  Collectively, these 
studies underscore the important role of FXR1P in normal muscle development.   
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MicroRNAs (miRNAs) are a class of small, genomically encoded RNAs that are ~22 
nucleotides in size and regulate translation by base pairing with sequences in the 3’UTR 
of target mRNA sequences (Bartel, 2004a, Bartel, 2009).  If base pairing is perfect along 
the ~22 nucleotide length, the result is mRNA target degradation (Bartel, 2004a, Bartel, 
2009). In contrast, if base-pairing occurs in the “seed” region at the 5’ end of the miRNA 
but is imperfect to the RNA, leading to a bulge in the duplex, the result is translational 
silencing (Bartel, 2004a, Bartel, 2009, Jackson et al., 2009).  miRNAs are estimated to 
regulate expression of greater than 1/3 of all expressed genes (Lewis et al., 2005, Nilsen, 
2007) but only a fraction of miRNAs have experimentally validated mRNA targets.  
Although the exact mechanism of how the mature miRNA finds its target mRNA is 
unclear, miRNAs function as part of larger complexes such as RNA induced silencing 
complex (RISC) and the miRNA ribonucleoprotein (miRNP) complex, suggesting that 
miRNAs guide associated proteins to target mRNAs to effect degradation, repression, or 
in some cases, translation activation (Fillipowicz et al., 2005, Vasudevan and Steitz, 
2007, Vasudevan et al., 2007, Cheever and Ceman, 2009a).  Once RISC separates the 
duplexed strands to produce a mature miRNA (Bartel, 2004a), the guide miRNA 
associates with Argonaute 2 (Ago2), the only human Argonaute family protein with 
endonuclease activity (Fillipowicz et al., 2005, Hock and Meister, 2008).  Incomplete 
complementarity of the miRNA to its target mRNA leads to translational repression, 
while complete complementarity triggers Ago2 endonuclease activity, leading to 
cleavage of the target mRNA, as observed during RNA silencing.  
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A number of miRNA target prediction programs are available to identify possible 
miRNA regulatory sites (Doran and Strauss, 2007).  Once a miRNA has been 
bioinformatically identified as a potential gene regulator, in vitro experiments using a 
luciferase reporter bearing the target sequence are used to determine whether the miRNA 
binds the 3’UTR of the target mRNA (Hurteau et al., 2007, Scott et al., 2007).  To 
address miRNA regulation of endogenous protein expression, researchers have 
overexpressed the candidate miRNA in the form of synthetic mimics or precursor 
miRNAs (pre-miRNAs) to examine regulation (Hurteau et al., 2007, Scott et al., 2007).  
These approaches have been used to identify the mRNA targets of miRNAs such as miR-
1, miR133, and miR-206 which are highly expressed in cardiac and skeletal muscle, and 
has led to insights into normal vertebrate cardiac and skeletal muscle development and 
function (Chen et al., 2006, Chen et al., 2008, Chen et al., 2009).   
Members of the fragile X family of proteins bind target mRNAs to regulate their 
translation (Terracciano et al., 2005); however, the molecular mechanisms underlying 
how FMRP or FXR1P regulate the translation of their mRNA cargoes remains unclear.  
Studies have shown that mammalian FMRP and FXR1P associate with Dicer, miRNAs, 
Ago2 and other miRNA pathway components (Bartel, 2004a, Jin et al., 2004b), 
suggesting that they utilize the miRNA pathway to regulate target mRNAs.  Recently, 
phosphorylation of FMRP was demonstrated to abolish association with Dicer, 
suggesting that phosphorylation regulates interaction of FMRP with the miRNA pathway 
(Cheever and Ceman, 2009a).  FXR1P was implicated in translation regulation when it 
was shown to be recruited with Ago2 by miRNAs bound to the 3’ untranslated region  
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(3’UTR) of TNFα mRNA in quiescent cells.  The result is upregulation of translation, 
suggesting that FXR1P plays a role in translation activation (Vasudevan and Steitz, 2007, 
Vasudevan et al., 2007).   
 
Although there is much interest in determining the mechanism by which the fragile X 
family of RNA binding proteins regulate expression of target mRNAs, the regulation of 
these translation regulators is not well understood.  We examined the expression of 
fragile X family members in a conditional Dicer knockdown cell line and found that 
FXR1P expression but not FMRP expression is regulated by miRNAs.  Further, we 
identified an 8-nucleotide seed sequence in the 3’UTR of FXR1 that is predicted to bind 
five different miRNAs and found that one of the miRNAs, miR-367, suppresses 
expression of FXR1P in HEK-293T and HeLa cell lines.  We provide the first evidence 
that FXR1P is regulated by miRNAs.  
 
Results 
Loss of Dicer expression leads to an increase in overall translation.   
To examine the role of miRNAs in the regulation of the fragile X family of proteins, we 
obtained a conditional loss-of-function Dicer cell line created in chicken B cell 
lymphoma DT40 cells (Fukagawa et al., 2004).  Conditional knockdown of Dicer was 
achieved by addition of tetracycline to the DT40 growth media every 24 hours for 96 
hours as previously described (Fukagawa et al., 2004), at which time a significant loss of 
Dicer expression was observed (Fig. 9A).  miRNAs are regulators of translation, 
primarily acting to suppress translation at the step of initiation (Meister, 2007).  To better 
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understand the effects of Dicer and subsequent miRNA knockdown on translation, we 
examined polyribosome (polysome) profiles in the presence (-tet) and absence (+tet) of 
Dicer.  Polysomes are mRNAs with one, two, three, four, etc., ribosomes associated with 
them, reflecting the translational state of the cell, and are visualized by UV absorption of 
fractionated lysates at 254 nm  (Ruan et al., 1997).  Examples of polysome profiles from 
mock treated DT40 cells and cells treated with tetracycline are shown in Fig. 9B.  In the 
presence of Dicer (-tet), none of the polysome peaks were as high as peak 1, which is 
typical (Khandjian et al., 1996, Feng et al., 1997, Ruan et al., 1997).  In contrast, in the 
absence of Dicer (+tet) and therefore, mature miRNA production, we reproducibly 
observed an increase in the amount of small polysomes (compare the height of peaks 3-5 
to 1), suggesting that there was an increase in translation initiation in the absence of 
miRNAs (Fig. 9B).  When we measured new protein synthesis in similarly treated cells 
by [3H]-methionine incorporation, we found that the absence of Dicer (+tet) led to an 
increase in the amount of labeled proteins (40% as measured by TCA incorporation [data 
not shown] and Fig. 9C), indicating increased protein synthesis in the absence of 
miRNAs.   
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Figure 9.  Loss of Dicer expression leads to a global increase in translation.  (A)  
DT40 cells were grown in the absence (-) or presence (+) of tetracycline (tet) for 96 
hours.  Cell extracts were made and 80 µg were examined by immunoblot for the proteins 
indicated on the right.   In the bottom panel, antibody 1C3 (left) was used to detect 
FXR1P and FMRP.  (B) DT40 cells were harvested after 96 hours of growth in the 
absence (-tet) or presence (+tet) of tetracycline.   Polysomes were obtained by protein 
fractionation through a sucrose gradient and measured at an absorption of 254 nm.  (1) 
indicates mRNAs with one ribosome, (2) indicates mRNAs with two ribosomes, etc.  (C) 
[3H]methyl-methionine, pulse-labeled protein extracts from DT40 cells grown for 96 
hours in the absence (-) or presence (+) of tetracycline were resolved on a 4-20% SDS-
PAGE gel. Molecular weight markers are shown to the left (kDa).  
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FXR1P but not FMRP is increased in the absence of Dicer.   
Proteins whose syntheses are increased in the absence of Dicer are potential candidates 
for miRNA-mediated regulation.  Thus, we chose to determine whether expression of 
FMRP and/or FXR1P was increased in the absence of Dicer expression.  To explore the 
regulation of FXR1P and FMRP, we first probed cell extracts for FMRP and FXR1P 
using monoclonal antibody 1C3 (Devys et al., 1993), which reacts with both proteins in 
mammalian cells (Mazroui et al., 2003).  By immunoblot, we found a large visible 
increase in the amount of the top band, but very little change in the bottom band (Fig. 1A, 
bottom panel).  Since DT40 is a chicken B cell line, we suspected that FXR1P was the 
top band and FMRP was the bottom band because both chicken and zebra finch FMRP 
are missing exons 11 and 12 (Price et al., 1996, Winograd et al., 2008); we therefore 
predicted that FMRP migrated faster in the gel.  To verify the identity of the proteins 
visualized by antibody 1C3 (Devys et al., 1993) in the DT40 cell line, we 
immunoprecipitated DT40 cellular extracts with an antibody specific to FXR1P and 
showed by 1C3 immunoblot that FXR1P was the top band (Fig. 10A).  Similarly, 
immunoprecipitation with two specific FMRP antibodies (Abcam) followed by 1C3 
immunoblot revealed that FMRP was the bottom band (Fig. 10B).  Thus, the loss of Dicer 
and miRNA production led to an increase in FXR1P expression but no change in FMRP 
expression.  
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Figure 10.  FXR1P has a larger size than FMRP in DT40 cells.  (A)  DT40 cells were 
grown for 96 hours in the absence (-) or presence (+) of tetracycline, 
immunoprecipitated with an anti-FXR1P specific antibody (Jin et al., 2004b) or an 
irrelevant antibody and immunoblotted with antibody 1C3 (Devys et al., 1993).  WCL- 
whole cell lysate.  (B) Immunoprecipitation with two independent FMRP specific 
antibodies (Abcam) and subsequent immunoblot with antibody 1C3 (Devys et al., 1993).  
Ig-(immunoglobulin) denotes immunoprecipitating antibody alone (B-above blot) or 
reactivity of HRP detecting antibody to Ig chains (B-right). 
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We repeated this experiment a number of times and consistently found an increase in 
FXR1P expression when Dicer was knocked down in DT40 cells (Fig. 11A). On average, 
FXR1P showed a 4-fold increase (p-value=0.009) in the absence of Dicer, while FMRP 
showed no significant increase in expression (Fig. 11B).  To definitively show that 
translation of FXR1P was increased in the absence of Dicer and suppressive miRNAs, we 
labeled cells with [3H]-methionine to visualize newly synthesized FXR1P and FMRP.  In 
the absence of miRNAs, there was more FXR1P synthesized compared to FMRP, whose 
translation levels remained the same (Fig. 11C).  Thus, we provide the first evidence for 
regulation of FXR1P, likely through the miRNA pathway.  
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Figure 11.  FXR1P but not FMRP is increased in the absence of Dicer.  (A)  DT40 
cells were harvested after 96 hours in the absence or presence of tetracycline (-tet, + tet, 
respectively)  and probed with 1C3 antibody (3).  Positions of FXR1P and FMRP are 
indicated to the right.  (B)  Quantification of fold-change of FXR1P and FMRP in the 
presence and absence of tetracycline as indicated. Significance was determined by  
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Figure 11.  (cont.)  
Students’s t-test.  (C)  Immunoprecipitation of DT40 after 96 hours of  -/+ tetracycline 
followed by [3H] methyl-methionine pulse-label.  Immunoprecipitating antibodies are 
indicated above the autoradiograms.  
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The absence of Dicer has no effect on FXR1 mRNA levels.   
miRNAs  regulate protein expression by either suppressing translation and/or increasing 
mRNA degradation (Bartel, 2004a, Nilsen, 2007).  To assess FXR1 mRNA levels in the 
absence of miRNAs, we performed quantitative reverse-transcription PCR on total RNA 
isolated from DT40 cells that were treated with tetracycline (+tet) or mock treated (-tet) 
(Fig. 12).  ΔCt values were calculated and averaged using triplicate samples from each of 
three independent trials. FMR1 mRNA levels were used as the internal control for 
normalization.  We found no significant difference in FXR1 mRNA levels in Dicer 
knockdown cells (Fig. 12).  The fact that FXR1 mRNA levels do not significantly change 
in the absence of Dicer also rules out the possibility that there was an increase in FXR1 
transcription due to miRNA-mediated heterochromatin changes.   We conclude that the 
increase in FXR1P expression in the absence of Dicer is not due to increased mRNA 
levels or transcription, but rather to a release of miRNA-mediated translation 
suppression. 
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Figure 12.  FXR1 mRNA levels do not significantly change in the absence of Dicer.  
DT40 cells were grown for 96 hours in the presence or absence of tetracycline  (-tet, 
+tet, respectively) and total RNA was extracted and reverse transcribed.  Quantitative 
real-time PCR using triplicate ΔCt values from three independent trials was used to 
calculate the 2-ΔCt and normalized to FMR1 mRNA levels.  Lack of significance was 
assessed by Z-test. 
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The 3’UTR of FXR1 contains putative miRNA regulatory sites.   
To identify potential miRNA regulatory sites in the 3’UTR of FXR1, we used Targetscan 
5.1 to predict miRNA binding sites in the 3’UTR (Fig. 13A). Each box represents the 
seed sequence of a single miRNA or the seed sequence shared by a group of miRNAs.  
Since functional miRNA regulatory sites have often been found near either the stop 
codon or the polyadenylation sequence of mRNA (Majoros and Ohler, 2007), we chose 
to focus on the shared seed sequence of miRNAs 25, 32, 92, 363, and 367 located near 
the polyadenylation sequence of the FXR1 3’UTR (Fig. 13A, circled miRNAs).   
 
Candidate miRNAs miR-92 and miR-363 are expressed in DT40 cells.   
miRNAs exhibit variable expression in cell lines, thus, we examined expression of the 
candidate miRNAs in DT40 cells.  We isolated total RNA from DT40 cells treated with 
tetracycline (+tet) and mock treated (-tet) DT40 and probed with [32P]-labeled antisense 
probes to candidate miRNAs (Fig. 13B and 13C).  miR-92 and miR-363 were expressed 
at detectable levels in DT40 cells and were present as pre-miRNAs in the absence of 
Dicer (+ lanes), as expected.  In contrast, we were unable to detect candidate miRNAs 32 
or 367 (data not shown) indicating they were either not expressed in DT40 cells or were 
below the detection limit of northern blotting. miR-25 was not tested.  Additionally, 
miRNAs 30a, 30a-5p, 31, 301, 199b, 200b, 429, and 124a (used as a negative control) 
were not detected in DT40 cells (data not shown). Thus, bioinformatically-identified 
miRNAs that bind seed sequences in FXR1’s 3’UTR are present in DT40 cells and are 
candidates for regulation of FXR1P expression. 
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Figure 13.  miR-92 and miR-363 are expressed in DT40 cells and have putative seed 
sequence regulatory sites in the FXR1 3’UTR.  (A) Schematic of the predicted location 
of all miRNA seed sequence binding sites (miRNAs labeled and seeds represented as 
boxes) in the FXR1 3’UTR based on TargetScan 5.1.  Bold boxes represent highly 
conserved sites.  Location of the 8 nucleotide seed sequence common to miRNAs-
25/32/92/363/367 is shown on the right and is circled.  miR-7 was predicted by 
TargetScan 5.1 but was not included in the FXR1 3’UTR subcloned luciferase constructs.  
(B)  Total RNA from DT40 cells treated with tetracycline for 96 hours (+) or mock 
treated (-) was extracted.  50 µg of total RNA was resolved on a 15% acrylamide  
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Figure 13.  (cont.) 
gel and probed with [32P]-labeled antisense oligos to miR-92 and miR-363, as indicated 
on the top.  Size in nucleotides is indicated to the left and positions of pre-miRNAs 
(upper band) and mature miRNAs (lower band) are indicated to the right. 
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The 3’UTR of FXR1 confers miRNA-mediated regulation on a reporter construct.   
To test our hypothesis that miRNAs regulate expression of FXR1P through its 3’UTR, 
we subcloned the FXR1 3’UTR downstream of the luciferase open reading frame in the 
pGL3 expression vector.  We expressed it in DT40 cells treated with tetracycline (+) or 
mock treated (-) cells and quantified luciferase expression.  Introduction of the 3’UTR of 
FXR1 increased the amount of luciferase expressed compared to the empty vector alone 
(pGL3) (Fig. 14A).  Importantly, we found that in the absence of Dicer (+) and 
consequently miRNAs, luciferase expression driven by the FXR1 3’UTR was 
significantly increased compared to its expression in the presence of Dicer (-) (Fig. 14A, 
compare +FXR1 to -FXR1).   (p-values<0.007).  Thus, the 3’UTR of FXR1 confers 
miRNA-mediated regulation on the luciferase reporter. 
 
To determine if the miRNA-mediated suppression of luciferase expression occurred 
through the 8-nucleotide seed sequence circled in Figure 13A, we removed this sequence 
and examined whether there was an effect on luciferase expression.  Deletion of the site 
increased luciferase expression in the presence of miRNAs compared to expression of the 
wild-type 3’UTR construct (Fig. 14A, compare –tet/+Dicer SDM to –tet/+Dicer FXR1), 
but not as much as global miRNA reduction (Fig. 14A, compare –tet/+Dicer SDM and 
+tet/-Dicer FXR1). Thus, removal of the miRNA binding site significantly abrogated 
some but not all of the miRNA-mediated suppression.  Further, simultaneous removal of 
the 8-nucleotide seed sequence and reduction of miRNAs significantly increased 
luciferase expression (+tet/-Dicer SDM), suggesting that the 8-nucleotide seed sequence 
regulates the 3’UTR of FXR1 through miRNA binding. As a control, we subcloned the 
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FMR1 3’UTR into the pGL3 expression vector and assessed luciferase expression in the 
presence and absence of Dicer (Fig. 14B).  We found that the absence of Dicer and 
mature miRNAs did not significantly increase expression of the luciferase construct (Fig. 
14B, compare –tet/+Dicer FMR1 to +tet/-Dicer FMR1).  Thus, the FXR1 3’UTR and, 
specifically, the 8 nucleotide seed sequence shared by miRNAs 25, 32, 92, 363, and 367 
confer miRNA-mediated regulation to the luciferase reporter constructs, while the FMR1 
3’UTR does not.  (p-values<0.007). 
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Figure 14.  miR-25/32/92/363/367 seed sequence binding site in the 3’UTR of FXR1 
confers miRNA-mediated regulation on luciferase constructs.  A. pGL3 luciferase 
reporter vector alone (pGL3), containing the 3’UTR of FXR1 (FXR1) or containing the 
FXR1 3’UTR in which the seed sequence common to miRNAs 25/32/92/363/367 was 
deleted (SDM) were electroporated into DT40 cells after 72 hours growth in the presence 
or absence of tetracycline.   
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Figure 14.  (cont.) 
24 hours after electroporation, (for 96 total hours in tetracycline), luciferase expression 
was assessed in DT40 cells grown in the presence (+) or absence (-) of tetracycline (tet).  
Transfection efficiency was monitored by Renilla expression and all luciferase values 
were normalized to empty vector (pGL3) in the absence of tetracycline.  Values are 
depicted as expression fold change compared to empty vector.  Significance was 
determined by Student’s t-test ** p-values<0.007 B.  pGL3 vector containing the FMR1 
3’UTR was electroporated into DT40 cells under the same conditions as described above.  
No significant difference in luciferase expression was observed in the presence (-) or 
absence (+) of miRNAs by student’s t-test. 
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To verify miRNA-mediated regulation of FXR1P in a cell line other than DT40, we 
overexpressed one of the miRNAs in HeLa and HEK-293T cells (Fig. 15).  Since the 
miR-25, 32, 92, 363, 367-group shares a common seed sequence, we predicted that 
overexpressing any one of them would repress FXR1P expression.  We chose miR-367 
because we found it expressed in DT40 cells (Fig. 13B).  HeLa and HEK-293T cells were 
transfected with a double-stranded miR-367 RNA mimic and harvested after 72 or 96 
hours (Fig. 15).  After assessing FXR1P expression, quantification showed a ~60% 
reduction (p-value<0.007) in FXR1P expression levels compared to control in HeLa cells 
(Fig. 15A).  In HEK-293T cells, there was an average reduction (p-value<0.05) of greater 
than 60% compared to the control (Fig. 15B).  Transfection of an irrelevant siRNAs did 
not affect FXR1P expression in either cell line (data not shown).  Thus, expression of a 
miRNA specific to the seed sequence common to miR-25, 32, 92, 363, and 367 is 
sufficient to significantly down-regulate FXR1P expression in two human cell lines. 
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Figure 15.  Overexpression of miR-367 reduces FXR1P expression.  HeLa (A) and 
HEK293 (B) cells were transfected with a miR-367 mimic.  72 or 96 hours post 
transfection, mimic transfected cells (miR-367) or mock transfected (Cntrl.) were 
harvested and probed for FXR1P and eIF5, as indicated to the right in top panels (A and 
B).  Densitometry was performed using Image J.  FXR1P expression was normalized to 
the eIF5 loading control before quantifying FXR1P expression on three independent 
experiments. Significance was calculated by Student’s t-test, HeLa ** p<0.007, HEK-
293 * p<0.05. 
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Discussion 
In the present study, we investigated miRNA-mediated regulation of FXR1P and FMRP 
by utilizing a conditional Dicer knockdown cell line DT40.  Reduced Dicer expression 
was used to effect a global reduction in mature miRNAs due to a lack of Dicer 
processing.  In the absence of miRNAs, we found a four-fold increase in FXR1P, without 
influencing FMRP expression (Fig. 12).  Regulation of FXR1P expression was further 
characterized by showing that miRNA-mediated regulation could be conferred on a 
luciferase reporter bearing the 3’UTR of FXR1 (Fig. 14).  We then showed that removal 
of an 8-nucleotide seed sequence that is conserved in mammalian and chicken orthologs 
reduced miRNA-mediated regulation (Fig. 14).  Finally, overexpression of miR-367 in 
two human cell lines resulted in a greater than 50% reduction in FXR1P expression (Fig. 
15).  Collectively, our data indicate that this site in the 3’UTR is important for regulation 
of FXR1P expression in multiple cell lines.   
 
FXR1, named ‘FMR-cross-reacting relative’, was first identified by screening a Xenopus 
laevis cDNA library with the human FMR1 gene (Siomi et al., 1995).  FXR1 has 86% 
amino acid sequence identity to FMR1 in the region containing the KH domains and is 
very similar to FMR1 over the amino-terminal domain (70% identity).  In contrast to 
FMR1, FXR1 orthologs have highly conserved 3’ UTRs (>90%), suggesting an 
important regulatory function (Siomi et al., 1995).  Our data suggest that the 3’UTR of 
FXR1 is translationally regulated.  Further, a recent study showed that the FXR1 mRNA, 
but not the FMR1 mRNA, is found associated with Ago2 in HEK293T cells, suggesting 
that the FXR1 mRNA is regulated by miRNAs (Hendrickson et al., 2008).  In a separate 
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study, also with the goal of identifying mRNAs regulated by miRNAs, high-throughput 
sequencing of mRNAs crosslinked to Ago2 failed to detect the FMR1 mRNA (FXR1 
was not tested) (Chi et al., 2009).  Finally, even though many miRNA binding sites are 
predicted in the FMR1 3’UTR, none of the miRNAs tested in that study bound the 
3’UTR, indicating a lack of functional miRNA binding (Chi et al., 2009).  Taken 
together, these findings support our data showing that expression of FXR1P, but not 
FMRP, is regulated by miRNAs.  However, we cannot rule out the possibility that 
FMRP could be regulated by miRNAs in specific cell types, like neurons. 
 
Although we mapped a regulatory region of the 3’UTR of FXR1 to the miR-25, 32, 92, 
363, 367 seed sequence, other miRNA binding sites may also play a role in regulating 
FXR1P expression.  Removal of the aforementioned seed sequence did not completely 
abolish miRNA-mediated regulation of the reporter construct and an even greater effect 
on expression was seen upon global miRNA reduction, suggesting that other miRNAs 
might regulate expression of FXR1P.  Recent data has shown that co-expressed miRNAs 
influence down-regulation of target genes more than individually expressed miRNAs 
(Ivanovska and Cleary, 2008).  Interestingly, miR-92a and miR-363 are co-expressed on 
the X chromosome and both were detected in DT40 cells, suggesting that both miRNAs 
are candidates for regulating FXR1P expression.  
 
miRNAs have been shown to regulate key transcription factors such as MYC, E2Fs and 
MYB (Xiao et al., 2007, Lal et al., 2009).  However, there is very little evidence for 
miRNA-mediated regulation of RNA binding proteins.  HuR is a sequence-specific RNA 
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binding protein that regulates translation and RNA turnover; which in turn influences the 
cellular response to stress, proliferative signals, immune triggers and developmental cues 
(Gorospe, 2003, Lopez de Silanes et al., 2005, Cherry et al., 2006, Abdelmohsen et al., 
2007).  HuR was recently shown to be regulated by miR-519 (Abdelmohsen et al., 2008).  
We now add FXR1P as an additional example of one postranscriptional regulatory factor 
(RNA binding protein) being regulated by another type of postranscriptional regulator 
(miRNAs). 
 
FXR1P is implicated in normal muscle development and function (Mientjes et al., 2004, 
Huot et al., 2005).  miRNAs are also critically important for normal muscle development 
and function (Wienholds and Plasterk, 2005, Chen et al., 2006, Chen et al., 2009).  In 
fact, comprehensive miRNA expression-profiling studies revealed that a total of 185 
miRNAs were dysregulated in samples of diseased muscle tissue from 10 different 
muscle disorders (Eisenberg et al., 2009).  miR-92, a candidate miRNA for FXR1P 
regulation, was found to be misregulated in Duchennes’ Muscular Dystrophy and in 
Nemaline Myopathy, a congenital myopathy that is the most common nondystrophic 
congenital myopathy (Eisenberg et al., 2009).  Thus, it is formally possible that FXR1P, 
and consequently its target mRNAs, are misregulated in muscle disease states as a result 
of misregulated miRNA expression. Understanding how FXR1P is regulated by miRNAs 
will give insight into normal muscle development and function.  
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Material and Methods 
Cell lines and antibodies 
The DT40 cell line was maintained in Dulbecco’s modified medium (Sigma D5796) 
supplemented with 10% tetracycline-free fetal calf serum (Clontech), 1% chicken serum, 
1% penicillin/streptomycin (Gibco), and 10 µM ß-mercaptoethanol (Fisher) (Buerstedde 
and Takeda, 1991).  Cell suspension concentration was maintained between 105 and 106 
per ml.  HeLa and HEK293 cell lines were maintained in Dulbecco’s modified medium 
supplemented with 10% fetal calf serum, 1% penicillin/streptomycin and 1% non-
essential amino acids.  Anti-FMRP antibody IAC-1C3, hereafter referred to as 
monoclonal antibody 1C3 (Devys et al., 1993) was used to detect both FMRP and FXR1P 
in immunoblots where indicated at a 1/10 dilution of the hybridoma supernatant.  Anti-
FXR1P 2107 was used to detect FXR1P in HeLa and HEK-293T cells by immunoblot as 
described (Bakker et al., 2000).  Anti-FXR1 was used to immunoprecipitate FXR1P as 
described (Jin et al., 2004b).  Anti-eukaryotic initiation factor 5 (eIF5) (Santa Cruz) was 
used for loading controls.  Rabbit anti-Dicer (Santa Cruz) was used to detect Dicer.  
Antibody reactivity was visualized using either an anti-mouse HRP conjugate (Jackson 
Immunoresearch) or an anti-rabbit HRP conjugate (GE Healthcare) and developed with 
ECL (GE Healthcare). 
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Dicer Knockdown 
DT40 cells were cultured as previously described and maintained at 6X105 cells/ml for 2 
days before addition of tetracycline dissolved in EtOH at a final concentration of 2ug/ml 
of media.  Freshly made tetracycline (+ tet) or vehicle only (EtOH, - tet) was added to 
cell media every 24 hours until cells were harvested at 96 hours.  Dicer knockdown was 
confirmed by immunoblot with Dicer antibody.  
 
Metabolic Labeling 
DT40 cells grown as described above for 96 hours were pre-incubated in methionine-free 
media [Gibco] supplemented with glutamine and 10% dialyzed FCS for 30 minutes 
before introducing 50 uCi/ml of 3H methyl-methionine [Amersham] for 45 minutes. The 
cells were then washed twice with ice-cold PBS and lysed with lysis buffer (50 mM Tris 
pH 7.6, 300 mM NaCl, 30 mM EDTA, 0.5% triton X-100 and a protease inhibitor tablet 
[Roche]) for 10 minutes.  Cytoplasmic extracts were prepared by spinning to remove the 
nuclei and either total extract was loaded or the lysate was immunoprecipitated with the 
anti-FXR1P antibody (Jin 2004) or anti-FMRP antibodies (Abcam) as described (Stetler). 
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Linear sucrose density gradient analysis of polysomes. 
DT40 cells grown as described above were treated for 15 minutes with cycloheximide 
(100 µg/ml). Linear 15%-45% sucrose gradients containing 100 mM KCl, 20 mM Tris 
(pH 7.5), 5 mM MgCl2 were prepared using a gradient maker (BioComp). Cells were 
washed in PBS and lysed in the buffer described above.  Postnuclear supernatants were 
overlayed on the gradient and centrifuged for 75 minutes at 188,000 x g at 4oC. Each 
gradient was fractionated into 1 ml fractions by bottom displacement using a gradient 
fractionator (Isco) with the ribosomal profile monitored at OD254 nm.  
 
RNA Isolation and Quantitative Reverse Transcription-Polymerase Chain Reaction: 
Total RNA was isolated using TriZol (Invitrogen) and reverse transcribed using random 
primers and superscript II reverse transcriptase (Invitrogen).  qRT-PCR was performed 
and ΔCt values calculated and averaged using triplicate samples from each of three 
independent trials in a BioRad iCycler using QuantiTect SYBR green (Qiagen).  PCR 
was performed by initial denaturation at 95°C for 15min followed by 40 cycles of 15sec 
at 94°C, 30sec at 55°C, and 30sec at 72°C.  The primers for FXR1 and FMR1 were 
validated and obtained from Qiagen using the QuantiTect Primer Assay System (Cat. 
Nos. QT01498000 and QT01501031 respectively).  Primer specificity was verified by 
melt curve analysis and fold change between FMR1 mRNA levels (internal control for 
mRNA level normalization) and FXR1 mRNA levels was calculated as 2-ΔCt.  Lack of 
significance was assessed by Z-test showing no significant difference between the FXR1 
mRNA level fold change and 1. 
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Reporter Gene Assay and Cell Electroporation 
DT40 were cultured and tetracycline was added for Dicer knockdown as described above.  
At 72 hours, 107 cells were transfected by electroporation with 25 µg reporter constructs 
containing the firefly luciferase gene and either the FXR1 3’UTR, the FMR1 3’UTR, or 
the mutated FXR1 3’UTR (SDM) (pGL3-promoter vector, Promega) and 10 µg of the 
Renilla luciferase phRL-Tk vector (Promega).  Transfection with empty pGL3-promoter 
vector served as the control and co-transfection with the Renilla luciferase reporter 
plasmid was performed for normalization of transfection efficiencies.  Following 
electroporation, cells were immediately transferred to individual T75 cell culture flasks, 
treated with either tetracycline or vehicle only (EtOH), and grown for an additional 24 
hours at which time (96 hours after initial tetracycline/EtOH treatment) 3x106 cells were 
assayed for luciferase expression and the remaining cells harvested for Dicer expression 
by immunoblot.  The luciferase assay was carried out using the Dual-Luciferase Reporter 
Assay (Promega) according to the manufacturer’s directions.  Luciferase activity was 
measured in a luminometer (LUMIstar OPTIMA Luminometer) programmed with 
OPTIMA software version 2.00.  
 
Overexpression of miR-367 mimic 
HEK293 and HeLa cells were cultured as described above and then plated at 2x105 in 12-
well dishes.  24 hours after plating, cells were transfected with 50ul of 2µM double 
stranded miR-367 mimic (Dharmacon) was transfected using Lipofectamine2000 
transfection reagent (Invitrogen).  Control cells were mock transfected using 
Lipofectamine2000 and each sample was compared to an untreated control.  After 72 or 
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96 hours, cells were harvested and lysed in 0.3M NaCl lysis buffer containing protease 
inhibitors (Roche) and the lysates run on a 7.5% TBE/acrylamide gel.  Blots were probed 
with anti-FXR1P 2107 to measure FXR1P expression and then eIF5 antibody to control 
for loading.  Reduction in FXR1P expression was quantified using densitometry (Image 
J) and after normalization to eIF5, calculated as a percent decrease compared to control.  
Significance of reduction was determined using Student’s t-test.   
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CHAPTER 4 
CONCLUSIONS 
 
The data presented in this dissertation is the culmination of the research I have conducted 
during my graduate studies in the laboratory of Dr. Stephanie Ceman.  The goal of this 
research was to understand how phosphorylation of FMRP affects association with the 
miRNA pathway and whether fragile X proteins FMRP and FXR1P are regulated by 
miRNAs.  The research presented here accomplishes these goals by showing that 
phosphorylation of FMRP modulates an association with the miRNA-mediated 
regulatory pathway and that FXR1P, but not FMRP, is regulated by miRNAs. 
 
Summary I:  Phosphorylation of FMRP inhibits association with Dicer 
The results presented in Chapter 2 describe how phosphorylation of FMRP acts as a 
switch to modulate association with Dicer, a crucial element of the miRNA processing 
pathway.  When we discovered that P-FMRP but not FMRP associated with large 
amounts of an ~80 nucleotide RNA species, it was hypothesized that phosphorylation 
interfered with some aspect of miRNA processing, rendering P-FMRP more likely to 
associate with 70-80 nucleotide precursor miRNAs instead of the 19-23 nucleotide 
mature miRNAs (Bartel, 2004a).  Dicer is the enzyme responsible for cleaving the 
precursor miRNA hairpin loop, generating the roughly 22 nucleotide miRNA duplex 
which is then ready for loading into RISC for further processing (Bernstein et al., 2001, 
Hutvagner et al., 2001, Winter et al., 2009).  If the phosphorylation of FMRP inhibited 
Dicer binding, the 80 nucleotide precursor miRNAs seen associated with P-FMRP could 
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be explained.  This hypothesis was confirmed by co-immunoprcipitation experiments and 
a capture assay using HeLa cells to show FMRP, but not P-FMRP, associated with Dicer.  
RNase treatment did not eliminate FMRP’s association with Dicer, suggesting a protein 
interaction (see Appendix I).  Based on our data, we proposed a new role for 
phosphorylation in the regulation of FMRP function where phosphorylation inhibits 
FMRP association with Dicer, a key enzyme in the generation of miRNAs.  As a 
consequence of reduced association with Dicer, we predicted that less miRNAs were 
available for association with target mRNAs bound by P-FMRP.  
 
We concluded that Dicer-FMRP association requires FMRP’s unphosphorylated region 
496-503 and that phosphorylation of FMRP abolishes this interaction.  If miRNAs are 
required for translation activation as recently described (Maroney et al., 2006, Vasudevan 
and Steitz, 2007, Vasudevan et al., 2007) and FMRP is involved in translation activation 
(Bechara et al., 2009), phosphorylation of FMRP would indirectly suppress translation by 
decreasing miRNA production through loss of Dicer binding (Fig. 8) (Cheever and 
Ceman, 2009b).  
 
Discussion I: Phosphorylation of FMRP inhibits association with Dicer 
We found that there were less miRNAs and a substantial increase in pre-miRNAs 
associated with P-FMRP.  There are two possible ways to reconcile our findings with the 
reported role of FMRP as a translational suppressor (Ceman et al., 2003, Narayanan et 
al., 2007).  The first is that phosphorylation may suppress translation by reducing the 
production of miRNAs, which must function as translation activators, as recently 
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described by Steitz’s group (Maroney et al., 2006, Vasudevan and Steitz, 2007, 
Vasudevan et al., 2007).  Thus, in the absence of activating miRNAs, translation of 
FMRP mRNA targets is suppressed.   
 
Alternatively, there could be two functions for P-FMRP:  one as a translational inhibitor 
by a molecular mechanism not yet elucidated and the second, described here, as a 
modulator for association with the miRNA pathway where dephosphorylation would 
allow FMRP to associate with Dicer which would then process pre-miRNAs in to mature 
miRNAs for translation of FMRP bound target mRNA transcripts.  It is possible that P-
FMRP sequesters miRNAs in an inactive form as pre-miRNAs until FMRP is 
dephosphorylated and pre-miRNAs are processed.  At this time, FMRP target mRNA 
translation would be suppressed by mature miRNAs.  Under these conditions, the P-
FMRP/pre-miRNA complex is “poised” to effect suppression of target mRNAs in a 
localized manner.  This fits with the Steitz data where miRNAs were shown to recruit 
specific proteins, including FXR1P, in order to induce activation of translation under 
specific cell conditions (Vasudevan et al., 2007).   
 
We propose that the complex containing FMRP, mRNAs and pre-miRNAs is present in 
the cytoplasm and dephosphorylation of FMRP is the signal which allows Dicer to bind 
and process miRNAs for activation of translation.  Although we cannot yet distinguish 
between these possible scenarios, we can conclude that we have discovered a new role 
for phosphorylation in the regulation of FMRP function as an inhibitor of its association 
with Dicer, a key enzyme in the generation of miRNAs.  
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Future studies I 
1.  Identify the precursor microRNAs associated with phosphorylated FMRP 
Future experiments will need to be done to identify which precursor miRNAs (pre-
miRNAs) associate with P-FMRP.  It is also formally possible that P-FMRP, as a RNA-
binding protein with several RNA binding domains, associates with available pre-
miRNAs, perhaps through one of its KH domains.  This hypothesis is supported by in 
vitro data showing that recombinant FMRP aids Dicer processed miRNA assembly onto 
target mRNAs by acting as an acceptor protein through its KH domains (Plante et al., 
2006).    
 
In order to identify at least one of the pre-miRNAs associating with P-FMRP, we used a 
protocol adapted from Current Protocols in Mol Bio supplement 72 26.4.1-18 in an 
attempt to clone and sequence the pre-miRNAs.  We first extracted RNA associated with 
P-FMRP and FMRP using the immunoprecipitation and end-labeling protocol described 
in chapter 2.  Then, unlabeled RNA was run on a gel and compared to an identically 
prepared lane of radio-labeled RNA, along with a size marker.  This allowed us to excise 
the un-labeled RNA aligning to the 70-80 nucleotide region of pre-miRNAs.  After 
elution from the gel, RNA was precipitated and dephosphorylated to prevent 
circularization during T4 RNA ligation.  Phosphorylated 3’ and 5’ adapters were labeled 
and ligated onto the RNA, which was then ready for reverse transcription, followed by a 
second PCR step to add a Ban1 restriction site to both ends of the cDNA.  The resulting 
construct was then cloned into a TA cloning vector (Invitrogen) for screening and 
sequencing.    
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Unfortunately, the resulting sequence did not match any known precursor or mature 
miRNA sequences.  One confounding factor in this experiment was the starting amount 
of RNA.  While the protocol we used is optimized for a starting amount of RNA in the 
microgram range, the amount of RNA obtained from our immunoprecipitation and 
extraction protocol was in the picogram range.  It was concluded that the starting amount 
of RNA was too low to ascertain its identity using this cloning protocol.  
 
Assuming the ~80 nucleotide band seen associating with P-FMRP is precursor miRNAs, 
an alternative to the above experiment would be to use the NCodeTM Multi-Species 
miRNA Microarray (Invitrogen).  This service includes cloning and probing for all 
miRNA species in human, mouse, rat, Drosophila, C. elegans, and zebrafish.  The arrays 
are done in triplicate, contain controls to monitor hybridization specificity, and have 
positive and negative controls throughout the array.  In order to utilize this method, 
putative P-FMRP associating pre-miRNAs would need to be processed into mature 
miRNAs.  Treating the extracted RNA with recombinant Dicer (Genlantis) could process 
pre-miRNAs into miRNAs that could then be detected by this microarray.   
 
2.  Does phosphorylation of FMRP modulate miRNA-mediated translation 
activation of target mRNAs? 
Assuming a validated P-FMRP associating pre-miRNA could be identified, future 
experiments could be done to determine whether, following de-phosphorylation of 
FMRP, Dicer association could process P-FMRP associated pre-miRNAs into a mature 
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miRNAs.  One hypothesis is that translation activation of specific mRNAs associated 
with non-phosphorylated FMRP could occur, similar to the reported translational 
activation function of FXR1P (Vasudevan and Steitz, 2007, Vasudevan et al., 2007).  To 
test whether phosphorylation of FMRP modulates miRNA-mediated translation 
activation, Stek cells (which contain no endogenous FMRP) could be transfected with a 
constitutively phosphorylated (aspartic acid substitution at serine 499) FMRP construct 
(Asp) or a non-phosphorylated (alanine substitution at serine 499) FMRP construct (Ala) 
(Ceman et al., 2003), along with a putative FMRP-associating miRNA for use in a 
reporter assay.  In this scenario, transfection of Stek cells with Ala and a luciferase 
construct bearing a complementary miRNA sequence that is known to associate with 
FMRP would allow Dicer-FMRP binding.  The presence of Dicer would allow miRNA 
processing and lead to luciferase expression.  Alternatively, transfection with Asp and the 
luciferase-miRNA construct would lead to a lack of Dicer binding and, hence, no 
luciferase expression.  Together, these experiments would attach functional relevance to 
FMRP’s association with the miRNA pathway by showing a direct effect of a miRNA on 
translation of a target. 
 
Summary II:  Fragile X protein family member FXR1P is regulated by miRNAs  
In addition to FMRP’s utilization of the miRNA pathway to regulate target mRNAs, the 
close association of both FMRP and FXR1P with the miRNA pathway suggested possible 
miRNA-mediated regulation of these proteins themselves.  The results presented in 
Chapter 3 addressed the question of whether the fragile X proteins FMRP and FXR1P are 
regulated by miRNAs. 
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In order to better understand miRNA-mediated translation regulation, we obtained a 
Dicer conditional knockdown cell line, DT40.  We were able to use this cell line to test 
whether FMRP and FXR1P were regulated by miRNAs due to the global reduction in 
mature miRNAs due to a lack of Dicer processing.  In the absence of miRNAs, we found 
a four-fold increase in FXR1P, without influencing FMRP expression (Fig. 10).  
Collectively, our data indicate that a regulatory site in the 3’UTR of FXR1 is important 
for regulation of FXR1P expression in multiple cell lines.  In addition, it suggests that 
FMRP is not regulated by miRNAs. Understanding how FXR1P is regulated by miRNAs 
will give insight into normal muscle development and function.  We can now add FXR1P 
as an additional example of one postranscriptional regulatory factor (RNA binding 
protein) being regulated by another type of postranscriptional regulator (miRNAs). 
 
Discussion II: Fragile X protein family member FXR1P is regulated by miRNAs 
Although we have identified an important miRNA regulatory site in FXR1, our data does 
not exclude the possibility of other miRNA binding sites playing a role in FXR1P 
regulation.  The aforementioned seed sequence did not completely abolish miRNA-
mediated regulation of the reporter construct because an even greater effect on expression 
was seen when there was global miRNA reduction.  Further experiments to sequentially 
delete other miRNA binding sites in the FXR1 3’UTR will determine whether other 
miRNAs could regulate expression of FXR1P and if there are combinatorial effects of 
multiple miRNA binding sites.    
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FXR1P is critically important for normal muscle development and function (Mientjes et 
al., 2004, Huot et al., 2005, Wienholds and Plasterk, 2005, Chen et al., 2006, Chen et al., 
2009).  miR-92, one candidate miRNA we identified for FXR1P regulation, was found to 
be misregulated in Duchennes’ Muscular Dystrophy and in Nemaline Myopathy, a 
congenital myopathy that is the most common nondystrophic congenital myopathy 
(Eisenberg et al., 2009).  Thus, it is formally possible that FXR1P, and consequently its 
target mRNAs, are misregulated in muscle disease states as a result of misregulated 
miRNA expression.  However, it remains to be seen whether FXR1P levels themselves 
change throughout normal muscle development and how this relates to miRNA 
expression levels.   
 
Future studies II 
1.  Examine effect on miRNA knockdown on endogenous FXR1P expression 
Although we have shown that absence of the seed sequence common to this group of 
miRNAs increases expression of a luciferase construct bearing the FXR1 3’UTR and 
shown a decrease in endogenous FXR1P expression upon miR-367 overexpression, we 
have not knocked down all of these miRNA in order to show an increase in endogenous 
FXR1P expression.  Our preliminary data shows that knockdown of miR-92 with an 
antagomir (Ambion) does not increase FXR1P expression to a detectable level in HEK-
293T cells.  However, since all of these miRNAs share the same seed sequence, if any 
one of miRNAs-25, 32, 92, 363, or 367 are expressed in HEK-293T cells, they could 
suppress translation of FXR1P, thereby confounding the results of the miR-92 antagomir 
experiment.  Consequently, it is important to verify which miRNAs are expressed in the 
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cell line used to examine the effects of miRNA knockdown on FXR1P expression levels.  
We obtained this information for HeLa and HEK-293T cells from The Swiss Institute of 
Bioinformatics (http://www.mirz.unibas.ch/cloningprofiles/) website, showing that 
miRNAs 25, 32, and 92 are expressed in HeLa cells and miRNAs 32 and 92 in HEK-
293T cells.  Since these lists may not be comprehensive, knockdown of only these 
miRNAs may not have an effect on endogenous FXR1P expression.  Therefore, antisense 
locked nucleic acid (LNA) probes specific for miRNAs 25, 32, 92, 363, and 367 could be 
used to knockdown these miRNAs and examine FXR1P expression levels in these cell 
lines.   
 
2.  Identify other miRNA regulatory sites in the FXR1 3’ untranslated region 
It is possible that there are other miRNA binding sites within the FXR1 3’UTR that 
regulate FXR1P expression.  In order to identify these other miRNA regulatory sites, 
systematic deletion of regions within the FXR1 3’UTR and cloning of these mutants into 
luciferase vectors for use in reporter assays (as described in chapter 3) could be utilized.  
Using TargetScanHuman 5.1, the FXR1 3’UTR can be divided into roughly three sections 
with multiple miRNA binding sites.  Region one extends from nucleotides 13-104 and 
region two from nucleotides 328-629.  Region three contains the regulatory site we 
identified and described here and one other miRNA binding site, miR-7/7ab which was 
not present in our luciferase constructs and therefore was concluded to have no additional 
effect on FXR1P expression.  Site directed mutagenesis (Stratagene) to delete these 
regions, insertion into pGL3 luciferase reporter vector and electroporation of these 
constructs into tetracycline treated Dicer cells to assess luciferase expression could then 
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be performed.  If one region was seen to effect luciferase expression, additional, smaller 
deletions constructs could be made to narrow the miRNA binding sites down even 
further.  In this way, mapping of the combinatorial effects of multiple regulatory miRNA 
binding sites could lead to a hierarchy of regulatory sites, with increasing effects on 
FXR1P expression levels.   
 
3.  Utilize a muscle cell line to observe FXR1P expression and regulation 
Since FXR1P is implicated in muscle development and disease, examining its expression 
levels and miRNA regulation in a muscle cell line should be investigated.  We have 
preliminary data showing that FXR1P expression increases substantially over a 24 hour 
period in C2C12 cells.  This change in FXR1P expression level could be miRNA 
mediated.  In order to test this hypothesis, the miR-367 mimic (described in chapter 3) 
will be used to overexpress miR-367 in the C2C12 cells.  If it regulates FXR1P in this 
cell line and plays a role in mediating the increase in expression seen over a 24 hour 
period, its overexpression should abolish this increase in FXR1P expression.  If correct, 
this would supply the first evidence for miRNA-mediated regulation of FXR1P in a 
muscle cell line. 
 
Concluding remarks 
FMRP and FXR1P are important regulators of messenger RNAs.  The absence of FMRP 
in fragile X syndrome and the dysregulation of FXR1P in muscle disorders can be 
attributed to serious human diseases.  Unraveling how post-translational modifications 
and miRNAs modify their ability to regulate cellular processes and how they themselves 
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are regulated will aid in understanding their complex functions, and ultimately, the 
disease states associated with each one.  Our work on FMRP and FXR1P in the context 
of the miRNA-mediated regulatory pathway provides a framework for a better 
comprehension of both these proteins. 
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APPENDIX A 
 
 
Introduction 
We have shown that the Dicer enzyme binds unphosphorylated fragile X mental 
retardation protein (FMRP) on residues 496-503 and phosphorylation of FMRP (P-
FMRP) at this site abolishes Dicer association (Chapter 2) (Cheever and Ceman, 2009a).  
We further showed that this interaction is not RNA mediated by performing co-
immunoprecipitation experiments in the presence of RNase and observing that Dicer and 
FMRP continue to associate.  Although FMRP and P-FMRP peptides were used in 
capture assays to confirm that Dicer association occurred at FMRP’s phosphorylation site 
(residues 496-503) (Ceman et al., 2003), these experiments do not confirm a direct 
interaction between FMRP and Dicer.  Hence, either Dicer or a Dicer-containing complex 
binds unphosphorylated FMRP.   
 
We attempted to determine whether there was a direct interaction between FMRP and 
Dicer and map the interaction site using a yeast-2-hybrid approach.  Based on our 
previous data, if Dicer and FMRP interact, deletion of FMRP’s phosphorylation site 
should abolish this interaction. We expected a direct interaction between FMRP and 
Dicer based on our in vitro capture assay and co-IP data.  This appendix details the 
process of cloning Dicer into a yeast vector and outlines the attempt to establish a direct 
protein interaction between Dicer and FMRP.  The end result of the experiment was not 
informative because co-expression of FMRP and Dicer in yeast was lethal. 
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Materials and methods 
Plasmids and strains 
Mouse Dicer cDNA corresponding to Genbank accession number AF408401 (Nicholson 
and Nicholson, 2002) was a gift from Dr. Allen Nicholson.  FMRP subcloned into the 
two-hybrid bait vector pGBKT7 was obtained from Dr. Edward Khandjian.  This 
construct has been shown  to express full length FMRP in yeast (Davidovic et al., 2006).  
 
Clontech protocols, yeast strains, and vectors were used throughout the assay.  
S. cerevisiae two-hybrid bait strain AH109 (MATa, trp1-901, leu2-3, 112, ura3-52, his3-
200, gal4Δ, gal80Δ, LYS2::GAL1UAS-GAL2TATA-ADE2 URA3::MEL1UAS-MEL1TATA-
lacZ MEL1) was transformed with either the pGADT7-GAL4 activation domain (AD) 
fusion two-hybrid vector containing full-length Dicer sequence (pGADT7-Dicer), or 
pGADT7 containing the SV40 large T-antigen sequence (pGADT7-T). 
S. cerevisiae two-hybrid prey strain Y187 (MATα, ura3-52, his3-200, ade2-101, trp1-
901, leu2-3, 112, gal4Δ, gal80Δ, met-, URA3::GAL1UAS-GAL1TATA-lacZ MEL1) was 
transformed with either the pGBKT7-GAL4 DNA binding domain (BD) fusion two-
hybrid vector containing full-length FMRP sequence (pGBKT7-FMRP), pGBKT7 
containing p53 sequence (pGBKT7-53), or pGBKT7 containing human lamin C sequence 
(pGBKT7-LAM). 
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Results 
Two-hybrid assay 
Cloning of Dicer into the pGADT7 yeast vector was first attempted by engineering 
flanking sfi1 restriction sites into Dicer cDNA (6.5 kb), then ligating this construct into 
the sfi1 site of the yeast prey vector, pGADT7, which contains the activation domain that 
binds the yeast GAL4 UAS of the minimal promoter required to activate the yeast lacZ 
reporter gene.  However, this construct could not be successfully expressed and 
propagated in bacteria cells, probably due to the large size of the Dicer protein (~220 
kDa).  Since yeast cells are highly efficient in carrying out homologous recombination, 
cloning of Dicer into pGADT7 was then attempted in yeast instead of bacteria (Ma et al., 
1987).  Flanking sequences complementary to  ~40 nucleotide overhangs corresponding 
to the EcoR1 and BAMH1 restriction sites in the pGADT7 yeast vector were added by 
PCR to the starting and ending sequence of the Dicer cDNA respectively.  Since yeast 
will carry out homologous recombination to “repair” the gap in the vector, digested 
pGADT7 vector and the Dicer construct containing pGADT7 overhangs were 
simultaneously transformed into yeast strain AH109.  Transformants were selected by 
growth on YPDA media lacking leucine.  Subsequent yeast colony PCR, western blot and 
sequencing confirmed correct insertion of Dicer into pGADT7 and expression of full-
length Dicer in yeast (Fig. 16).    
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Figure 16. Cloned full-length Dicer in the pGADT7 two-hybrid vector.  Four yeast 
colonies (AH109) were transformed with full-length Dicer containing flanking pGADT7 
overhangs and digested pGADT7.  Following protein extraction (Clontech), Dicer was 
expression was detected in three of the four colonies (Lanes 1, 3, and 4).  Yeast 
transformed with empty vector (pGADT7- Vector only) served as a negative control for 
Dicer expression.   
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The FMR1 sequence in the yeast bait vector, pGBKT7, containing the binding domain for 
the yeast GAL4 UAS of the minimal promoter required to activate the yeast lacZ reporter 
gene (Dr. E. Khandjian) was transformed into the Y187 yeast strain and transformants 
were selected by growth on YPDA media lacking tryptophan (data not shown). 
 
Once the constructs were successfully transformed into their respective yeast strains, 
verification by western blot of bait and prey expression was again performed.  Both Dicer 
and full-length FMRP were expressed in yeast (Fig. 17).  To determine whether Dicer 
and FMRP interacted directly, we mated yeast containing the respective FMRP-binding 
domain (bait) and Dicer-activation domain (prey).  A direct interaction would have been 
indicated by colonies able to grow on triple dropout (-LEU2, -TRP1, -HIS) media.  
 
The SV40 large T-antigen (pGADT7-T) with murine p53 (pGBKT7-53) has been shown 
to interact in a yeast-2-hybrid and was used as the positive control.  The Human lamin C 
(pGBKT7-LAM), has been shown to neither form complexes nor interact with SV40 
large T-antigen (pGADT7-T) and was used as a negative control.  
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Figure 17.  Verification of FMRP and Dicer expression in yeast transformants.   
Yeast lysate probed with either anti-HA antibody (Covance) (Blot #1, a and b) or anti-
myc antibody (Blot #2, c) in order to verify Dicer, FMRP, large T antigen, and p53 
expression prior to mating.  (a.)  Blot #1 was probed with anti-HA and exposed for 10 
minutes on film.  Histidine tagged Dicer was detected, clone 3-5 (lane 1) and clone 7-4 
(lane 2) .  Lane 3 is described in part (b).  Lane 4- negative control:  untransformed 
AH109 whole cell lysate without Dicer or large T-antigen expression.  (b.)  Blot #1 was 
again exposed for 2 minutes on film in order to observe large T-antigen expression in 
Lane 3.  (c.)  Blot #2 was probed with anti-myc.  Lane 1- p53 expression.  Lane 2- myc-
tagged full-length FMRP.  Lane 3 was loaded with Human lamin C expressing yeast 
lysate but was not detectable on the western blot.  Lane 4- negative control: 
untransformed AH109 whole cell lysate without FMRP of p53 expression.  
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Table 1.  Mating crosses:  Yeast two-hybrid. 
 
                           AH109: 
 
 
Y187: 
 
 
- Denotes zero yeast colonies 
++ Denotes greater than 50 yeast colonies  
 
Yeast strain Y187 containing the constructs shown on the left were crossed with yeast 
strain AH109 containing the constructs shown across the top.  No colonies were observed 
where indicated (-); yeast colonies were observed when p53 interacted with large T-
antigen where indicated (++).  Crosses were screened on triple dropout media (-LEU, -
TRP, -HIS).  
 
 
 
 
 
 
Y187 X AH109 
-LEU, -TRP, -HIS 
pGADT7-Dicer pGADT7-T 
pGBKT7-FMRP - - 
pGBKT7-53 - ++ 
pGBKT7-LAM - - 
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Discussion 
We could not verify a direct protein interaction between FMRP and Dicer using a yeast 
two-hybrid assay.  Although both FMRP and Dicer could be expressed independently in 
the two separate yeast strains, mating and co-expression of these proteins proved to be 
lethal in yeast (table 1). 
 
If a direct interaction had been established, FMRP deletion constructs (Fig. 18) which 
have already been cloned into the yeast bait vector pGBKT7 would have been 
transformed into yeast and mated with the Dicer construct.  This would have allowed 
mapping of where the direct interaction between FMRP and Dicer occurs on the FMRP 
protein.  Since our previous data indicate there is an interaction between Dicer and FMRP 
at residues 496-503 between exons 14 and 15, a positive result using these constructs in a 
yeast two-hybrid would depend on whether each FMR1 construct contained this intact, 
non-phosphorylated region.  As shown in Figure 18, only when there is a constitutively 
phosphorylated mutant (Asp) (Ceman et al., 2003) or a lack of this region (only exons 16 
and 17 present) would a lack of Dicer binding be expected.  
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 Figure 18.  Predicted results of yeast two-hybrid interaction between Dicer and 
FMRP deletion constructs.  The FMR1 exon map (above) shows the exons present in 
the FMR1 gene, the location of the functional domains with respect to the exons and the 
location of the phosphorylation site.  1. An FMR1 construct containing exons 14, 15, 16, 
and 17 would be expected to interact with Dicer.  2.  An FMR1 construct containing 
exons 14-17 but with an alanine (Ala) or aspartic acid (Asp) substitutions at serine 499, 
the primary FMRP phosphorylation site, would be expected to interact with Dicer as 
shown to the right.  3.  An FMR1 construct containing only exons 16 and 17 would not be 
expected to interact with Dicer.  4.  An RGG box deletion would not be expected to affect 
Dicer association.  
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It is possible that an intermediate protein provides a link between FMRP and Dicer in 
vivo.  Had the yeast two-hybrid technically worked and we had seen no interaction, we 
would have assumed this to be the case.  Bridging proteins could be identified by 
immunoprecipitating FMRP and probing with antibodies to candidate proteins.  Two 
likely candidates would be Ago2 based on previous studies showing it is present in 
miRNP complexes (Hutvagner and Simard, 2008) containing FMRP (Jin et al., 2004a), 
and FXR1P, which has been shown to be in miRNP complexes involved in translation 
activation (Vasudevan et al., 2007).  Alternatively, one could determine whether 
phosphorylation of FMRP disrupts the FMRP-bridging protein association by 
immunoprecipitating with PSER and probing for the candidate bridging proteins.  Mass 
spectrometry of proteins that co-immunoprecipitate with P-FMRP compared to FMRP 
would also reveal whether Dicer is differentially bound and if there are additional 
associating proteins based on FMRP’s phosphorylation state. 
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